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BLACK BEAR PARATHYROID HORMONE 
AND METHODS OF USING BLACK BEAR 
PARATHYROID HORMONE
STATEMENT REGARDING 
FEDERALLY-SPONSORED RESEARCH
This invention was made with United States government 
support awarded by the National Institutes of Health (NIAMS 
AR050420, NIDDK DK078407 and AA143990) and the 
National Science Foundation (IBN-0343515). The United 
States government has certain rights in this invention.
CROSS-REFERENCE TO RELATED 
APPLICATIONS
This application claims priority and is a national stage 
filing under 35 U.S.C. 371 of International Application No. 
PCT/US2009/066974, filed Dec. 7, 2009. This application is 
incorporated herein by reference in it’s entirety.
BACKGROUND
Bone loss diseases are currently a health threat for approxi­
mately 44 million Americans, including 10 million with 
osteoporosis and 34 million with low bone mass and at risk 
for developing osteoporosis. The number of Americans with 
osteoporosis is expected to rise by 2020. Consequently, a 
large number of individuals are at risk for bone fracture due to 
low bone mass. Approximately 40% of white women and 
13% of white men over age 50 are at risk for hip, spine, or 
forearm fracture within their lifetime. The costs associated 
with osteoporosis-related fractures were approximately $18 
billion dollars in 2002, and are expected to continue climbing. 
In addition to primary (age-related) osteoporosis, disuse 
osteoporosis is an important clinical problem, especially for 
patients chronically immobilized due to stroke or spinal cord 
injury. Fracture rates double compared to healthy controls in 
the first year following spinal cord injury and are also elevated 
compared to healthy controls after the onset of stroke. Disuse 
increases fracture rates primarily because reduced skeletal 
loading causes unbalanced bone remodeling which leads to 
bone loss.
SUMMARY
In certain embodiments, the invention provides an isolated 
polypeptide comprising at least 10 consecutive amino acid 
residues of SEQ ID NO: 2 wherein the polypeptide comprises 
at least one of amino acid residues 41 and 52 of SEQ ID NO: 
2. In certain embodiments, isolated polypeptides comprising 
amino acid residues 1-84 of SEQ ID NO: 2 are provided. 
Polynucleotides encoding such polypeptides are also pro­
vided. The present invention also provides an isolated poly­
nucleotide comprising SEQ ID NO: 1.
In certain embodiments, the invention provides a method 
of increasing c AMP levels in a bone-forming cell comprising 
contacting the bone-forming cell with an effective amount of 
at least one polypeptide selected from a polypeptide compris­
ing amino acid residues 1 -34 of SEQ ID NO: 2, a polypeptide 
comprising amino acid residues 1-36 of SEQ ID NO: 2, a 
polypeptide comprising amino acid residues 1 -84 of SEQ ID 
NO: 2, wherein contacting the bone-forming cell with the 
polypeptide increases cAMP levels in the bone-forming cell.
In certain embodiments, the invention provides a method 
of reducing apoptosis in a bone-forming cell comprising con­
tacting the bone-forming cell with an effective amount of at
1
least one polypeptide selected from a polypeptide comprising 
amino acid residues 1-34 of SEQ ID NO: 2, a polypeptide 
comprising amino acid residues 1-36 of SEQ ID NO: 2, a 
polypeptide comprising amino acid residues 1 -84 of SEQ ID 
NO: 2, wherein contacting the bone-forming cell with the 
polypeptide reduces apoptosis in the bone-forming cell.
In certain embodiments, the invention provides a method 
of decreasing the ratio of expression levels of Bax protein to 
Bcl-2 protein in a bone-forming cell comprising contacting 
the bone-forming cell with an effective amount of at least one 
polypeptide selected from a polypeptide comprising amino 
acid residues 1 -34 of SEQ ID NO: 2, a polypeptide compris­
ing amino acid residues 1-36 of SEQ ID NO: 2, a polypeptide 
comprising amino acid residues 1-84 of SEQ ID NO: 2, 
wherein contacting the bone-forming cell with the polypep­
tide decreases the ratio of expression levels of Bax protein to 
Bcl-2 protein in the bone-forming cell.
In certain embodiments, the invention provides a method 
of increasing the expression level of a bone matrix protein, a 
transcriptional activator, or a transcriptional regulator in a 
bone-forming cell comprising contacting the bone-forming 
cell with an effective amount of at least one polypeptide 
selected from a polypeptide comprising amino acid residues 
1 -34 of SEQ ID NO: 2, a polypeptide comprising amino acid 
residues 1-36 of SEQ ID NO: 2, a polypeptide comprising 
amino acid residues 1-84 of SEQ ID NO: 2, wherein contact­
ing the bone-forming cell with the polypeptide increases the 
expression level of the bone matrix protein, the transcrip­
tional activator, or the transcriptional regulator in the bone­
forming cell.
In certain embodiments, the invention provides a method 
of enhancing bone mineral density, increasing bone mass, 
decreasing bone loss, or reducing the incidence of bone frac­
tures, or any combination thereof, in a subject, comprising 
contacting a bone-forming cell in the subj ect with an effective 
amount of at least one polypeptide selected from a polypep­
tide comprising amino acid residues 1-34 of SEQ ID NO: 2, 
a polypeptide comprising amino acid residues 1-36 of SEQ 
ID NO: 2, a polypeptide comprising amino acid residues 1-84 
of SEQ ID NO: 2, wherein contacting the bone-forming cell 
with the polypeptide enhances bone mineral density, 
increases bone mass, decreases bone loss, or reduces the 
incidence of bone fractures in the subject.
In certain embodiments, the invention provides a method 
of enhancing bone mineral density, increasing bone mass, 
decreasing bone loss, or reducing the incidence of bone frac­
tures, or any combination thereof, in a subject, comprising 
contacting a bone-forming cell in the subj ect with an effective 
amount of a polypeptide comprising bear parathyroid hor­
mone or a functional fragment thereof, wherein contacting 
the bone-forming cell with the polypeptide enhances bone 
mineral density, increases bone mass, decreases bone loss, or 
reduces the incidence of bone fractures in the subject.
In certain embodiments, the invention provides an isolated 
polypeptide consisting of amino acid residues 1-34 of SEQ 
ID NO: 2. In certain embodiments, the invention provides an 
isolated polypeptide consisting of amino acid residues 1-36 
of SEQ ID NO: 2. In certain embodiments, the invention 
provides an isolated polypeptide consisting of amino acid 
residues 1-84 of SEQ ID NO: 2.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 shows ultimate stress, a measure of bone strength, 
and ash fraction, a measure of bone mineral content, which 
both increase with age in black bears.
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FIG. 2 shows that serum osteocalcin levels are positively 
correlated with serum parathyroid hormone (PTH) levels 
(p=0.0007, n=27) in black bears for pooled pre-hibernation, 
hibernation, and post-hibernation samples.
FIG. 3 shows normalized serum resorption (ICTP) and 
formation (PICP and osteocalcin) marker concentrations dur­
ing the 3 month disuse period.
FIG. 4 shows that the amount of PGE2 released by osteo­
blastic cells was greatest when the cells were treated with 
serum collected in the post-hibernation period.
FIG. 5 shows the sequence of the mature black bear PTH 
protein compared to other known PTH sequences.
FIG. 6 shows that both human and black bear PTH 1-34 
upregulate osteocalcin (n=2).
FIG. 7 shows the effects of human and black bear PTH 1-34 
on apoptosis-related gene expression (n=4).
FIG. 8 shows uCT images of a proximal rat tibia (left), 1.6 
mm analysis region of cortical and trabecular bone starting 2 
mm distal to the proximal physis (top right), and the trabecu­
lar analysis region (bottom right).
FIGS. 9A-9F show pCT images of bones from rats follow­
ing sham ovariectomy (OVX) (FIG. 9A) or actual OVX fol­
lowed by six (FIG. 9B) or fourteen (FIG. 9C) weeks of recov­
ery with no PTH treatment, or by fourteen weeks of recovery 
including eight weeks of treatment with 3 pg/kg (FIG. 9D), 10 
pg/kg (FIG. 9E), or 30 pg/kg (FIG. 9F) black bear PTH1-34.
FIG. 10 shows a graph of bone volume as a fraction of total 
volume (BV/TV) for bones from rats having had sham or 
actual OVX procedures followed by treatment with vehicle 
(saline) or human or bear PTH 1-34.
FIG. 11 shows a graph of bone mineral apparent density for 
bones from rats having had sham or actual OVX procedures 
followed by treatment with vehicle (saline) or human or bear 
PTH1-34.
FIG. 12 shows a graph of trabecular strut number for bones 
from rats having had sham or actual OVX procedures fol­
lowed by treatment with vehicle (saline) or human or bear 
PTH1-34.
FIG. 13 shows a graph of trabecular thickness for bones 
from rats having had sham or actual OVX procedures fol­
lowed by treatment with vehicle (saline) or human or bear 
PTH1-34.
FIG. 14 shows a graph of trabecular bone mineralization 
for bones from rats having had sham or actual OVX proce­
dures followed by treatment with vehicle (saline) or human or 
bear PTH 1-34.
FIG. 15 shows a graph of tibial cortical bone volume for 
bones from rats having had sham or actual OVX procedures 
followed by treatment with vehicle (saline) or human or bear 
PTH1-34.
FIG. 16 shows a graph of tibial cortical porosity for bones 
from rats having had sham or actual OVX procedures fol­
lowed by treatment with vehicle (saline) or human or bear 
PTH1-34.
FIG. 17 shows a graph of femoral cortical bone strength for 
bones from rats having had sham or actual OVX procedures 
followed by treatment with vehicle (saline) or human or bear 
PTH1-34.
FIG. 18 shows a graph of serum calcium levels of rats 
having had sham or actual OVX procedures followed by 
treatment with vehicle (saline) or human or bear PTH1-34.
FIG. 19 shows the relative caspase-3 activity in MC3T3-S4 
cells pretreated with 0-100 nM human or bear PTH peptides 
and then subjected to serum starvation. LS means with stan­
dard error bars are presented. Bars with different letters are 
significantly (p<0.05) different from each other.
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FIG. 20 shows ultimate load of the femur in OVX rats 
treated with vehicle (V), 2.5 nmol/kghPTHl-84, or 2.5 nmol/ 
kg bbPTHl-84.
FIG. 21 shows normalized ultimate load of the femur in 
OVX rats treated with vehicle (V), 2.5 nmol/kghPTHl-84, or 
2.5 nmol/kg bbPTHl-84.
FIG. 22 shows bone volume fraction in OVX rats treated 
with vehicle (V), 2.5 nmol/kg hPTHl-84, or 2.5 nmol/kg 
bbPTHl-84.
FIG. 23 shows trabecular number in OVX rats treated with 
vehicle (V), 2.5 nmol/kg hPTHl -84, or 2.5 nmol/kg bbPTHl- 
84.
FIG. 24 shows trabecular thickness in OVX rats treated 
with vehicle (V), 2.5 nmol/kg hPTHl-84, or 2.5 nmol/kg 
bbPTHl-84.
FIG. 25 shows trabecular separation in OVX rats treated 
with vehicle (V), 2.5 nmol/kg hPTHl-84, or 2.5 nmol/kg 
bbPTHl-84.
FIG. 26 shows apparent mineral density in OVX rats 
treated with vehicle (V), 2.5 nmol/kg hPTHl -84, or 2.5 nmol/ 
kg bbPTHl-84.
FIG. 27 shows material mineral density in OVX rats treated 
with vehicle (V), 2.5 nmol/kg hPTHl-84, or 2.5 nmol/kg 
bbPTHl-84.
FIG. 28 shows caspase 3/7 activity in cells cultured in 
prehibernation, hibernation, and posthibernation bear serum.
FIG. 29 shows ultimate load of femurs in mice treated with 
vehicle or various PTH peptides.
DETAILED DESCRIPTION
In humans and most other mammals, factors such as aging 
and extended periods of disuse can lead to osteoporosis and 
an increased risk of fracture. Disuse due to spinal cord lesion 
significantly decreases bone mineral density, particularly in 
the tibia and femur, and significantly reduces the cross-sec­
tional moment of inertia of the femoral diaphysis. Thus, bone 
bending strength is reduced by spinal cord injury and fracture 
risk is increased. Disuse due to stroke also increases fracture 
risk. In addition, mechanical unloading of bone can cause 
rapid bone loss due to immediate increases in bone resorption 
in addition to sustained decreases in bone formation. Disuse- 
induced changes in bone remodeling increase intracortical 
porosity, and reduce the cross-sectional and mechanical prop­
erties of long bone diaphyses. Unloading also considerably 
reduces trabecular bone mass and microarchitecture.
The deleterious effects of disuse onbone may continue into 
the remobilization period. Some bone may be recovered dur­
ing remobilization, but recovery is slow and often incom­
plete. For example, the rate of bone loss during bedrest is 
more than three times greater than the rate of bone gain during 
remobilization, and the recovery of bone lost in spaceflight 
can be incomplete even after 5 years. When disuse-induced 
changes in bone can be completely reversed by resumed 
activity, the remobilization period is often 2 to 3 times longer 
than the immobilization period. Bone formation decreases 
and/or bone resorption increases in many situations that 
reduce mechanical loads on bone. However, both resorption 
and formation increase during canine forelimb immobiliza­
tion, yet there is significant bone loss in that case. Likewise, 
thigh bone turnover occurs in patients with spinal cord injury, 
which leads to bone loss and increased fracture incidence.
In contrast to this, black bears do not suffer significant bone 
loss due either to aging (FIG. 1) or, more importantly, to the 
extended periods of disuse that occur during hibernation. 
Hibernating black bears have immobilization and active peri­
ods that can be approximately equal in length in northern
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regions. Data on serum markers of bone metabolism (see 
below) suggest that both resorption and formation increase 
during disuse in bears, with a normal lag time (i.e., reversal 
period) between resorption and formation, and that the 
increase in formation remains coupled and balanced with the 
increase in resorption. Histological data from black bear iliac 
crest biopsies also show increased resorption and formation 
during inactivity. However, bears are unique in that trabecular 
bone volume, bone mineral density, and bone mineral content 
do not decrease during hibernation. Moreover, cortical bone 
strength and ash fraction increase with age, and porosity 
decreases with age in black bears, despite annual periods of 
disuse. Cortical bone porosity is significantly lower in hiber­
nating grizzly bears than in active grizzly bears, and femoral 
cross-sectional geometry and strength are unaffected by 
hibernation.
Bears have evolved many unique biological mechanisms to 
survive long periods of immobilization without food. These 
mechanisms appear to include the recycling of calcium and 
other products of bone catabolism, since bears increase bone 
turnover but do not excrete waste during hibernation. In 
humans, bedrest-induced disuse osteoporosis is caused pri­
marily by increased resorption without a corresponding 
increase in formation. This results in hypercalcemia and a 
negative calcium balance brought about by increased urinary 
and fecal calcium. Since bears do not urinate or defecate 
during hibernation, it is likely that most of the calcium 
released from bone by resorption is recycled back into bone 
via osteoblastic bone formation. Ionized calcium is found to 
increase by about 23% during hibernation, possibly because 
of the lag time between resorption and formation. Paradoxi­
cally, black bear PTH levels are highest when levels of ion­
ized calcium are highest (Example 2, Table 1). Taken 
together, these findings suggest that bears have evolved bio­
logical mechanisms to avoid osteoporosis.
The mechanisms that uncouple bone formation from 
resorption during disuse in most animals are unknown, but 
likely involve both mechanical and biochemical factors. Lack 
of mechanical strain may lead to increased resorption by 
initiating osteocyte apoptosis and concomitantly reducing 
osteoblastic activity. Hormones such as human PTH can sen­
sitize bone cells to mechanical stimulation and synergisti- 
cally, with mechanical loading, increase bone formation. 
Human PTH given once daily to humans increases bone mass 
and decreases fracture incidence. Thus, in black bears, circu­
lating PTH may sensitize bone cells to low levels of mechani­
cal stimulation (possibly due to shivering or repositioning in 
the hibernaculum) to help maintain bone formation during 
disuse. PTH may also help maintain bone formation in black 
bears by stimulating osteoblast differentiation and inhibiting 
osteoblast apoptosis.
PTH is the primary regulator of blood calcium levels, and 
thus plays a role in maintaining homeostatic serum calcium 
levels in black bears during disuse. Serum PTH levels are 
positively correlated with the bone formation marker osteo­
calcin in active and hibernating black bears (FIG. 2), and both 
osteocalcin and PTH increase during hibernation. In addition, 
black bear PTH concentration is highest when ionized cal­
cium concentration is highest. Since bone resorption 
increases during hibernation but total serum calcium (tCa) 
remains unchanged, increased levels of PTH likely cause 
increased renal reabsorption of calcium, facilitating the recy­
cling of mineral back into the bone with a balanced increase 
in bone formation. This leads to the observed preservation of 
trabecular and cortical bone properties like bone mineral 
density (“BMD”) and cortical porosity. Bone resorption 
increases during hibernation, but blood calcium concentra­
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tion remains constant despite the fact that bears do not excrete 
waste during hibernation. The calcium liberated by bone 
resorption during hibernation may be recycled and put back 
into bone by maintaining balanced coupling of bone forma­
tion with bone resorption. This supports the idea that PTH has 
anabolic effects in hibernating black bears and provides an 
explanation for the bears’ distinctive ability to maintain bal­
anced bone remodeling during hibernation. The anabolic 
effects of PTH may be enhanced in black bears when physical 
activity is resumed following arousal from hibernation. 
Mechanical loading and human PTH have previously been 
shown to act synergistically to increase bone formation in 
vivo in rats and biochemical signaling in vitro. During remo­
bilization in the spring, bone formation in the black bear, as 
indicated by serum osteocalcin, remains higher than pre­
hibernation levels.
The sequence for the polynucleotide that encodes black 
bear (Ursus americanus) parathyroid hormone (PTH) (SEQ 
ID NO: 1) was discovered as well as the polypeptide sequence 
for the mature 84 amino acid PTH protein (SEQ ID NO: 2). In 
addition, the cDNA (SEQ ID NO: 3) which encodes the full 
length PTH protein (SEQ ID NO: 4), including a 25 amino 
acid signal peptide (amino acid residues 1-25 of SEQ ID NO: 
4) and a 6 amino acid propeptide (amino acid residues 26-31 
of SEQ ID NO: 4) has been sequenced. The mature black bear 
PTH protein differs from other known PTH proteins (FIG. 5). 
Compared to human PTH, black bear PTH has 9 different 
amino acid residues out of a total of the 84 amino acid resi­
dues of the full-length, mature PTH polypeptide. Also 
described herein are various methods of use for black bear 
PTH and functional fragments thereof. It is specifically envi­
sioned that polypeptide sub fragments comprising at least 10 
consecutive amino acid residues of SEQ ID NO: 2 and includ­
ing at least one of amino acid residues 41 or 52 can be used to 
develop antibodies specific for black bear PTH. These anti­
bodies can be used to quantify black bear PTH, e.g. in an 
ELISA assay.
PTH receptors on the surface of bone-forming cells are 
coupled to cyclic adenosine monophosphate (cAMP)-depen- 
dent second-messenger signaling pathways inside the cells. 
These signaling pathways, in turn, lead to increased expres­
sion of genes involved in bone formation such as those encod­
ing type I collagen, osteonectin, and osteopontin. Since the 
cAMP/protein kinase A pathway is responsible for the major­
ity of PTH-induced increases in histological and serum indi­
ces of bone formation, it follows that an increased cAMP 
response can lead to greater bone formation. A relatively 
small number of amino acid substitutions in the sequence of 
a given PTH protein can stimulate greater cyclic adenosine 
monophosphate (cAMP) production compared to the native 
form. For example, ovariectomized rats demonstrated a 25% 
greater bone formation response to daily 25 pg injections of 
bovine PTH 1-34 than to rat PTH 1-34, where rat PTH 1-34 
has 5 amino acid sequence differences compared to bovine 
PTH 1-34. Injection of bovine PTH 1-34 results in a 37% 
greater increase in bone volume fraction during treatment.
Thus, it is likely that the amino acid substitutions in black 
bear PTH cause it to induce greater cAMP production in 
bone-forming cells than human PTH. PTH, in general, elicits 
a greater bone formation response by mechanisms such as 
decreasing osteoblast apoptosis, increasing osteoblast differ­
entiation via Runx2, downregulating SOST-based negative 
feedback in osteocytes, and increasing production of mRNA 
for bone matrix proteins, all via cAMP-mediated pathways. 
Although it is not necessary to understand the mechanism of 
an invention, it is believed that black bear PTH is likely more 
osteogenic than other forms of PTH, which explains why
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black bears are uniquely able to maintain balanced bone 
remodeling during disuse. In certain embodiments of the 
present invention, contacting a bone-forming cell with black 
bear PTH or a functional fragment thereof increases cAMP 
levels in the bone-forming cell. In certain embodiments of the 
present invention, the bone-forming cell is contacted with a 
polypeptide comprising amino acid residues 1-34 or 1-36 of 
SEQ ID NO: 2. In certain embodiments of the present inven­
tion, the bone-forming cell is contacted with a polypeptide 
comprising SEQ ID NO: 2.
As used herein, “contacting a cell” with a PTH polypeptide 
includes adding the polypeptide to the culture solution, in the 
case of in vitro experiments, or administering the polypeptide 
to a subject using appropriate administration procedures for 
polypeptide therapeutic agents. “Contacting a cell” also 
includes introducing into a subject an exogenous polynucle­
otide that encodes the desired polypeptide in an expression 
system so as to synthesize and release the polypeptide in the 
subject. As used herein, “bone-forming cells” includes, but is 
not limited to, osteoblasts, osteocytes, bone lining cells, 
chondroblasts, and chondrocytes. Suitably, the bone-forming 
cell may be in a subject.
Bone-forming cells regularly turn over, with most of the 
cells ’ death being due to programmed cell death, or apoptosis. 
Given this regular rate of turnover, any mechanism that 
decreases apoptosis of bone-forming cells will lead to an 
increased number of bone-forming cells which presumably 
will promote bone growth. Thus, in certain embodiments of 
the present invention, contacting a bone-forming cell with 
black bear PTH or a functional fragment thereof reduces 
apoptosis in the bone-forming cell. In certain embodiments of 
the present invention, the bone-forming cell is contacted with 
a polypeptide comprising amino acid residues 1-34 or 1-36 of 
SEQ ID NO: 2. In certain embodiments of the present inven­
tion, the bone-forming cell is contacted with a polypeptide 
comprising SEQ ID NO: 2.
Moreover, it is possible that several of the larger C-terminal 
fragments of endogenous black bear PTH play a role in sea­
sonal bone remodeling processes via binding to CPTHRs 
(C-terminal PTH receptors). Specifically, C-terminal frag­
ments of bear PTH may antagonize the calcemic effects of 
PTH 1-84 and 1-34 by preventing osteoclastogenesis and 
possibly by affecting mature osteoclast activity that would 
normally occur in response to resorptive stimuli such as dis­
use (Divieti, P. et al., 2002, Endocrinology 143(1): 171-6). 
This may help bears to maintain homeostatic calcium levels 
throughout hibernation. Thus, in certain embodiments of the 
present invention, osteocytes and osteoblasts may be con­
tacted with at least one polypeptide selected from a polypep­
tide comprising amino acid residues 11-84 and a polypeptide 
comprising amino acid residues 7-84 of SEQ ID NO: 2.
The protein Bax promotes apoptosis while the Bcl-2 pro­
tein protects cells from apoptosis, and a decrease in the 
expression ratio of Bax to Bcl-2 is indicative of a decrease in 
apoptosis in the particular cell population. Thus, in certain 
embodiments of the present invention, contacting a bone­
forming cell with black bear PTH or a functional fragment 
thereof decreases the ratio of expression levels of Bax protein 
relative to expression levels of Bcl-2 protein in the bone­
forming cell. In certain embodiments of the present invention, 
the bone-forming cell is contacted with a polypeptide com­
prising amino acid residues 1-34 or 1-36 of SEQ ID NO: 2. In 
certain embodiments of the present invention, the bone-form­
ing cell is contacted with a polypeptide comprising SEQ ID 
NO: 2.
Example 11 shows that black bear PTH 1-34 decreases the 
expression ratio of Bax/Bcl-2 in cultured cells whereas
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human PTH 1-34 increases the expression ratio of Bax/Bcl-2 
(FIG. 7). Thus, black bear PTH 1-34 appears to be more 
effective at preventing apoptosis than human PTH 1-34. 
Without being bound by theory, this difference may be the 
result of the two amino acid differences between human and 
black bear PTH 1-34. These data suggest that bear PTH is 
more anabolic than human PTH, since decreased osteoblast 
apoptosis may contribute to the bone formation response 
induced by PTH treatment.
Contacting a bone-forming cell with black bear PTH or a 
functional fragment thereof also increases the expression 
level of bone matrix protein, a transcriptional activator, or a 
transcriptional regulator in the bone-forming cell. In certain 
embodiments of the present invention, the transcriptional 
activator is Runx2. In certain embodiments of the present 
invention, the transcriptional regulator is c-fos. Exemplary 
bone matrix proteins include, but are not limited to, osteocal­
cin, osteopontin, and type I collagen. In certain embodiments 
of the present invention, the bone-forming cell is contacted 
with a polypeptide comprising amino acid residues 1-34 or 
1 -36 of SEQ ID NO: 2. In certain embodiments of the present 
invention, the bone-forming cell is contacted with a polypep­
tide comprising SEQ ID NO: 2.
Exogenous human PTH is used to treat post-menopausal 
and age-related osteoporosis in humans, but it is not an ideal 
therapeutic. Only recombinant human PTH 1-34 (LY333334, 
Eli Lilly, Indianapolis Ind.) is currently approved for clinical 
use, and only one form of recombinant human PTH 1-84 is 
under consideration for approval by the U.S. Food and Drug 
Administration (ALX1-11, NPS Pharmaceuticals, Parsip- 
pany, N.J.). Though LY333334 and ALX1-11 can stimulate 
approximately the same magnitude of bone formation in vivo, 
their biological actions are not identical. For example, PTH 
1-34 down-regulates production of procollagen-1 mRNA, 
whereas PTH 1-84 does not (Nasu et al., 1998, Endocr J, 45, 
229-34). In addition, it has also been determined that the 
C-terminal portion of human PTH, when cleaved from the 
mature hormone, has important biological functions such as 
inhibition of bone resorption.
Long-term usage of either LY333334 or ALX1-11 gener­
ates osteosarcoma in rats, but preliminary results indicate that 
human PTH 1-84 has a lower rate of carcinogenicity than 
human PTH 1-34, possibly because C-terminal fragments of 
exogenous human PTH 1-84 (arising from peripheral pro­
teolytic processing) can bind to C-terminal PTH receptors 
(CPTHRs) and increase osteocyte apoptosis. Thus, though 
equally anabolic, human PTH 1-84 may be a superior 
osteoporosis therapy compared to human PTH 1-34. How­
ever, human PTH 1-84 cannot completely restore lost bone; it 
has been suggested that men and women can lose between 
20-30% of cortical and cancellous bone due to age-related 
osteoporosis, but only 8% is recovered using ALX1-11 dur­
ing its suggested treatment regimen. Therefore, there exists a 
clinical need for osteoporosis treatments with greater osteo­
genic capabilities.
In certain embodiments, the present invention is a method 
of treating osteroporosis comprising administering an effec­
tive amount of black bear PTH or a functional fragment 
thereof to a subject in need thereof. In various embodiments, 
the osteoporosis is primary or age-related osteoporosis and/or 
disuse osteoporosis. In certain embodiments of the present 
invention, contacting a bone-forming cell in a subject with 
black bear PTH or a functional fragment thereof increases 
bone mineral density, increases bone mass, decreases bone 
loss orreduces the incidence of bone fracture in the subject. In 
certain embodiments of the present invention, the bone-form­
ing cell is contacted with a polypeptide comprising amino
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acid residues 1-34 or 1-36 of SEQ ID NO: 2. In certain 
embodiments of the present invention, the bone-forming cell 
is contacted with a polypeptide comprising SEQ ID NO: 2.
Suitably, contacting a bone-forming cell in a subject with 
black bear PTH or a functional fragment thereof increases 
bone mineral density, increases bone mass, decreases bone 
loss or reduces the incidence of bone fracture by at least about 
5% or at least about 10%. The increase in bone mineral 
density, increase in bone mass, decrease in bone loss or reduc­
tion in the incidence of bone fracture may be at least about 
15%, at least about 30%, at least about 50%, at least about 
75% or at least about 90%. The increase in bone mineral 
density, increase in bone mass, decrease in bone loss or reduc­
tion in the incidence of bone fracture is determined by mea­
suring the desired characteristic on the same patient before 
and after treatment by a technique known to one of ordinary 
skill in the art. For example, bone mineral density can be 
determined by methods involving taking dual energy x-rays 
(DEXA) orCT scans of bones in the spinal column, wrist, arm 
or leg.
The subject may suitably be a mammal, including without 
limitation human, horse, dog, cat, mouse, bear, bovine, pig, or 
deer. In certain embodiments, the subject is a post-meno- 
pausal human female. The subject may have osteoporosis or 
may be at risk to develop osteoporosis. Risk factors for devel­
oping osteoporosis include: personal history of fracture after 
age 50; current low bone mass; history of fracture in a first- 
degree relative; being female; being thin and/or having a 
small frame; advanced age; a family history of osteoporosis; 
estrogen deficiency as a result of menopause, especially early 
or surgically induced; abnormal absence of menstrual periods 
(amenorrhea); anorexia nervosa; low lifetime calcium intake; 
vitamin D deficiency; use of certain medications (corticoster­
oids, chemotherapy, anticonvulsants and others); presence of 
certain chronic medical conditions, such as those that 
decrease calcium absorption in the gut such as Crohn’s dis­
ease; low testosterone levels in men; an inactive lifestyle; 
current cigarette smoking; excessive use of alcohol; and 
being Caucasian or Asian; although African Americans and 
Hispanic Americans are at significant risk as well. Moreover, 
women can lose up to 20 percent of their bone mass in the five 
to seven years following menopause, making them more sus­
ceptible to osteoporosis.
Black bear PTH or functional fragments thereof are also 
useful as a preventative (rather than a restorative), or prophy­
lactic, measure to combat disuse osteoporosis or to prevent 
osteoporosis in a subject at risk for developing osteoporosis. 
Since bears appear to be the only animals that maintain bal­
anced bone remodeling during disuse, black bear PTH or 
functional fragments thereof are also useful to prevent bone 
loss during reduced skeletal unloading that occurs, for 
example, in astronauts during spaceflight and in spinal cord 
injury patients after injury.
Black bear PTH or functional fragments thereof may be 
administered in combination with calcium and/or vitamin D. 
Suitably, “Vitamin D” refers to the entire Vitamin D class of 
compounds. Black bear PTH or functional fragments thereof 
may also be administered in combination with other anabolic 
or antiresporptive active agents. Suitable anabolic active 
agents include various fragments of human PTH (e.g. 1-34 
and 1-84), fluoride, GH, insulin-like growth factor I, statins, 
and PYK2 kinase inhibitors. Suitable antiresorptive active 
agents include, but are not limited to estrogens, selective 
estrogen receptor modulators, calictonin, and bisphospho- 
nates. In certain embodiments, an anabolic functional frag­
ment of black bear PTH (e.g. black bear PTH 1 -34) is admin­
istered in combination with an antiresorptive active agent. In
9
certain embodiment, different functional fragments of black 
bear PTH may be administered in combination with each 
other. The different functional fragments may be adminis­
tered concurrently or in any order that is suitable.
The calcium, vitamin D, anabolic active agent, and/or anti­
resporptive active agent may be administered concurrently 
with black bear PTH or functional fragments thereof or may 
be administered before or after black bear PTH or functional 
fragments thereof. The calcium, vitamin D, anabolic active 
agent, and/or antiresporptive active agent may be in a separate 
composition or may be in the same pharmaceutical compo­
sition as the black bear PTH or functional fragments thereof.
Administration of black bear PTH or functional fragments 
thereof or compositions comprising black bear PTH or func­
tional fragments thereof can be accomplished by any suitable 
technique. Black bear PTH or functional fragment thereof 
may be administered by any suitable route including, for 
example, oral, nasal, rectal, and parenteral routes of admin­
istration. As used herein, the term parenteral includes but is 
not limited to subcutaneous, intradermal, intravenous, intra­
muscular, intraperitoneal, and intrathecal administration, 
such as by injection. As is discussed above, administration of 
a polypeptide includes administration of an exogenous poly­
nucleotide operably connected to a promoter such that the 
polynucleotide expresses the polypeptide in the subject. 
Administration of the polypeptide also includes administra­
tion of a viral vector comprising a polynucleotide encoding 
the polypeptide. Suitably, the viral vector is an adenoviral 
vector.
Black bear PTH or functional fragments thereof, or com­
positions comprising black bear PTH or functional fragments 
thereof, can be administered continuously or at discrete time 
intervals as can be readily determined by a person skilled in 
the art. An ordinarily skilled clinician can determine a suit­
able amount of black bear PTH or a functional fragment 
thereof to be administered to a subject.
The effective dose for any particular subject will depend 
upon a variety of factors, including the disorder being treated 
and the severity of the disorder; activity of the specific com­
pound employed; the specific composition employed; the 
age, body weight, general health, sex and diet of the subject; 
route of administration; the rate of excretion or inactivation of 
black bear PTH or functional fragments thereof employed; 
the duration of the treatment; other pharmaceuticals used in 
combination or coincidental with black bear PTH or func­
tional fragments thereof and like factors well known in the 
medical arts. For example, it is well within the level of ordi­
nary skill in the art to start doses at levels lower than those 
required to achieve the desired effect and to gradually 
increase the dosage until the desired effect is achieved.
Suitably, the dosage of black bear PTH or functional frag­
ments thereof in certain embodiments is in a range of 0.10 
pg/kg per day to 40 pg/kg per day. In certain embodiments, 
the dosage is in a range of 5 pg/kg per day to 20 pg/kg per day. 
In certain embodiments, the dosage is 10 pg/kg per day. In 
certain embodiments, the dosage is in a range of 10 pg/day to 
400 pg/day per subject. In certain embodiments, the dosage is 
in a range of 20 pg/day to 40 pg/day per subject. In certain 
embodiments, the dosage is 30 pg/day per subject.
F or combination administration, one of ordinary skill in the 
art would be able to determine the proper dosage of both the 
black bear PTH or functional fragment thereof and the addi­
tional active agent, such as calcium, vitamin D, anabolics or 
antiresporptives. As is discussed above, the effective dose for 
any particular subject depends on a variety of factors. In 
certain embodiments, the dosage of antiresorptives is about 5 
to about 100 mg per day, the dosage of calcium is from about
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500 to about 1500 mg per day, the dosage of vitamin D is from 
about 500 to about 1500 mg per day, the dosage of anaoblics 
is from about 0.1 mg to about 0.5 mg per day or about 10 
pg/day to 400 pg/day.
In certain embodiments the subject is a human. Suitably, 
the daily dosages in certain embodiments are given for one 
week, in certain embodiments for one month, in certain 
embodiments for three months, in certain embodiments for 
six months, in certain embodiments for one year, in certain 
embodiments for one and a half years, in certain embodi­
ments for two years, and in certain embodiments for three 
years.
If desired, the effective daily dose may be divided into 
multiple doses for purposes of administration. Consequently, 
single dose compositions may contain such amounts or sub­
multiples thereof to make up the daily dose. If desired, a 
suitable delivery device is loaded with the effective daily dose 
for more than one day, for example, for seven days, fourteen 
days, twenty-one days, twenty-eight days or the like, and the 
delivery device is used to repeatedly administer the desired 
daily single dose or daily multiple doses for the desired total 
number of days. As noted, those of ordinary skill in the art will 
readily optimize effective doses and co-administration regi­
mens as determined by good medical practice and the clinical 
condition of the individual subject.
Compositions containing black bear PTH or functional 
fragments thereof useful in the methods of the present inven­
tion can be formulated according to known methods for pre­
paring pharmaceutically useful compositions. Formulations 
are described in detail in a number of sources which are well 
known and readily available to those skilled in the art. For 
example, Remington’s Pharmaceutical Science, by E. W. 
Martin, describes formulations which can be used in the 
disclosed methods. In general, the compositions will be for­
mulated such that an effective amount of the black bear PTH 
or functional fragment thereof is combined with a suitable 
carrier in order to facilitate effective administration of the 
composition.
The compositions used in the present methods can also be 
in a variety of forms. These include, for example, solid, semi­
solid, and liquid dosage forms, such as tablets, pills, powders, 
liquid solutions or suspension, suppositories, injectable and 
infusible solutions, and sprays. The form will depend on the 
intended mode of administration and therapeutic application. 
The compositions also suitably include conventional pharma­
ceutically acceptable excipients which are known to those 
skilled in the art. Examples of excipients include water for 
injection, ethanol, dimethyl sulfoxide, glycerol, alumina, 
starch, glacial acetic acid, sodium acetate, mannitol, meta- 
cresol, hydrochloric acid and/or sodium hydroxide to adjust 
the pH of a composition to a suitable value, and equivalent or 
otherwise suitable carriers and diluents. To provide for the 
administration of such dosages for the desired application, 
pharmaceutical compositions will comprise between about 
0.1% and 99%, and suitably between about 1 and 15% by 
weight of the total of one or more of the polypeptides of the 
present invention based on the weight of the total composition 
including the carrier or diluent.
As used herein, an “isolated” nucleic acid molecule, poly­
nucleotide, polypeptide, or the like, as the case may be, refers 
to a component that is at least partially purified from contami­
nants (e.g., other species of polynucleotides, polypeptides, or 
the like) that is found other than in its natural state. An isolated 
nucleic acid, polynucleotide, or polypeptide may contain less 
than about 50%, suitably less than about 75%, and most 
suitably less than about 90%, of the cellular components with 
which it was originally associated. A polynucleotide ampli­
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fied using PCR so that it is sufficiently and easily distinguish­
able (on a gel, for example) from the rest of the cellular 
components is considered “isolated”. The nucleic acid mol­
ecules, polynucleotides, and polypeptides of the invention 
may be “substantially pure,” i.e., having the highest degree of 
purity that can be achieved using purification techniques 
known in the art.
As used herein, a “functional fragment” refers to any 
region or portion of a polypeptide or polynucleotide which is 
a region or portion of a laiger polypeptide or polynucleotide, 
the region or portion having an activity or function attribut­
able to the larger polypeptide or polynucleotide. For example, 
a functional fragment of human PTH is the 1-34 region of 
human PTH. Functional fragments of black bear PTH 
include, but are not limited to, 1-34 and 1-36.
As used in this specification and the appended claims, the 
singular forms “a,” “an,” and “the” include plural referents 
unless the content clearly dictates otherwise. It should also be 
noted that the term “or” is generally employed in its sense 
including “and/or” unless the content clearly dictates other­
wise. All publications, patents and patent applications are 
herein expressly incorporated by reference in their entirety 
for all purposes to the same extent as if each individual 
publication or patent application was specifically and indi­
vidually incorporated by reference. In case of conflict 
between the present disclosure and the incorporated patents, 
publications and references, the present disclosure should 
control.
It also is specifically understood that any numerical range 
recited herein includes all values from the lower value to the 
upper value, i.e., all possible combinations of numerical val­
ues between the lowest value and the highest value enumer­
ated are to be considered to be expressly stated in this appli­
cation. For example, if a concentration range is stated as 1% 
to 50%, it is intended that values such as 2% to 40%, 10% to 
30%, or 1% to 3%, etc., are expressly enumerated in this 
specification. If a concentration range is “at least 5%,” it is 
intended that all percentage values up to and including 100% 
are also expressly enumerated. These are only examples of 
what is specifically intended.
The following Examples are provided to assist in a further 
understanding of the invention. The particular materials, 
methods and conditions employed are intended to be illustra­
tive of the invention and are not limiting upon the scope of the 
invention.
Example 1
Sequencing of Black Bear PTH 1 -84 
Genomic DNA Extraction
Blood was collected from a captive female black bear and 
stored at 4° C. Genomic DNA was extracted from the whole 
blood samples within 2 weeks, using the GenomicPrep Blood 
DNA Isolation Kit (Amersham Biosciences, Piscataway, 
N.J.) according to the manufacturer’s instructions.
PCR Cloning and Sequencing
Black bear genomic DNA was used for PCR amplification 
of PTH, using consensus primers designed based on align­
ment of eight full-length mammalian PTH sequences avail­
able in GenBank including bovine (Bos taurus, AAA30749), 
cat (Felis catus, Q9GL67), dog (Cams familiaris, P52212),
human (Homo sapiens, NP_000306), macaque (Macaca fas-
cicularis, Q9XT35), mouse (Mus musculus, NP_065648),
pig (Sus scrofa, NP_999566), and rat (Rattus norvegicus,
NP_058740). PCR amplification was performed using 10-15
ng genomic DNA, 100 pM dNTPs, 0.2 pM each primer, and
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1 unit REDTaq (Sigma, St. Louis, Mo.) in 20 pL reaction 
volume. PCR products were gel-purified using the UltraClean 
GelSpin Kit (MoBio Carlsbad, Calif.) and cloned into the 
pCRII vector using the TA cloning kit (Invitrogen, Carlsbad, 
Calif.). DNA sequencing was performed using the DTCS 
Quick Start kit and the CEQ8000 Genetic Analysis System 
(Beckman Coulter, Fullerton, Calif.), following the manufac­
turer’s instructions.
Sequence Analysis
Nucleotide sequences were searched against the GenBank 
protein database using BlastX (Altschul et ah, 1997; Nucleic 
Acids Res., 25,3389-402) to confirm their putative identity as 
PTE1. Multiple sequence alignment was performed by Clust- 
alW version 1.82 (Chenna et ah, 2003; Nucleic Acids Res., 
31, 3497-500). Phylogenetic analysis was carried out using 
the neighbor-joining (NJ) method implemented in the 
Molecular Evolutionary Genetics Analysis (MEGA) package 
version3.0 (Kumaret al., 2004; BriefBioinform., 5,150-63), 
with the pairwise deletion option for handling alignment 
gaps, and with the Poisson correction model for distance 
computation.
PTE1 Cloning and Sequence Analysis
Various primer combinations were used for PCR-based 
cloning of PTE1 from black bear genomic DNA. Based on the 
sequencing results of preliminary clones, a gene-specific 
sense primer corresponding to the start codon was designed 
and used along with a degenerate antisense primer containing 
the stop codon to amplify the entire coding region of PTE1. A 
second antisense primer covering the stop codon was 
designed to generate a clone for sequence confirmation.
Sequence assembly revealed a precursor PTE1 protein of 
115 amino acids, including a 25 amino acid signal peptide and 
a 6 amino acid propeptide. The deduced mature protein is 84 
amino acids, with a calculated molecular weight of 9,471 
Daltons and a pi of 8.1. Black bear PTE1 shares 84-95% 
sequence similarity with other mammalian PTEls, and is most 
similar to dog PTE1 (91% identity, 95% similarity) (FIG. 5). 
Interestingly, two amino acid residues, 41 and 52 of the 
mature hormone, are unique to black bear PTF1.
Example 2
Levels of Bone Resorption and Formation Markers 
During Ffibernation
Serum Samples
Blood samples were collected from five black bears (Ursus 
americanus) held in a captive bear research facility. The Vir­
ginia Polytechnic Institute and State University Animal Care 
Committee approved all bear handling protocols (#98-069- 
F&WS). The bears were anesthetized with a 2:1 mixture of 
ketamine (100 mg/ml): xylazine (100 mg/ml); the dosage was 
1 cc of the mixture per 45.5 kg of body weight. Body tem­
peratures were 4° to 6° C. cooler during winter collection, 
confirming that the bears were in a state of hibernation. No 
urine or scat was present in the hibernation dens. Stressful 
behavior was not observed during any of the handling proce­
dures. Blood samples were drawn from the femoral vein 
while the bears were anesthetized, and the samples were 
transported to the laboratory in an ice-packed cooler. Imme­
diately on return to the laboratory, the blood was centrifuged 
to isolate the serum, which was frozen at -20° F. Blood 
samples were collected from each bear every 10 days from the 
first of October through the end of May. Ffibernation began in 
early January and ended in early April. Thus, the collection
13
dates encompassed an active pre-hibernation period, a disuse 
hibernation period, and an active post-hibernation remobili­
zation period.
Black Bear Osteocalcin Purification and RIA Procedures
Black bear cortical bone was broken into small fragments, 
defatted with a mixture of 3 parts hexane and 2 parts isopro­
panol, and lyophilized. The dried bone was ground to a fine 
powder under liquid nitrogen, and the osteocalcin was solu­
bilized as described by Flauschka et al. (1989, Physiol. Rev., 
69, 990-1047). Osteocalcin was purified from the resulting 
EDTA extract by a modification of the method of Colombo et 
al. (1993, J. Bone Miner. Res., 8, 733-43). Briefly, the crude 
EDTA solution was diluted 2-fold and passed over a bulk 
column containing 10 g Sepralyte C l8 particles (Analyt- 
ichem International, Flarbor City, Calif.) previously activated 
with methanol and equilibrated with 0.1% trifluoroacetic acid 
in water (0.1% TFA). An extensive wash with 0.1% TFA was 
followed by 30% methanol/0.1% TFA until UV absorbance 
dropped to baseline. Osteocalcin was eluted with 80% metha- 
nol/0.1% TFA. Methanol was evaporated under a stream of 
air and the remaining solution lyophilized. The resulting 
dried protein was suspended in 0.05 MTris buffer, pFl 8.0 and 
applied to a 5 ml Biorad Econo-Q column previously equili­
brated with the same buffer. The column was developed with 
a gradient from 0.1 to 0.6 M NaCl in 0.5 M Tris, pFl 8.0. 
Osteocalcin eluted in a symmetric peak, the last to elute from 
the column. Identity of this peak as osteocalcin was qualita­
tively verified by reacting fraction aliquots with diazoben­
zene sulfonic acid yielding a pink color in those fractions 
containing osteocalcin, with intensity corresponding to peak 
height. Both the Cl 8 and the Econo-Q column were new and 
never exposed to protein from other species. Previous expe­
rience with other species suggests the final osteocalcin peak is 
greater than 99% pure. Concentration of black bear osteocal­
cin in the final elute was determined with BCA reagents from 
Pierce Chemical (Rockford, 111.).
Biochemical Assays
The serum was assayed for PTF1, 25-OF1 D, leptin, IGF-I, 
and osteocalcin (a bone formation marker) using RIA and 
ELISA.
Flighly purified black bear osteocalcin and black bear 
serum were assayed by radioimmunoassay. The antibody was 
guinea-pig anti-rat osteocalcin and tracer was 1251-labeled 
rat osteocalcin. Dose dilutions of both rat osteocalcin stan­
dard (Biomedical Technologies, Inc, Stoughton, Mass.) and 
purified black bear osteocalcin were included in the assay. 
Aliquots of 10 pi black bear serum per assay tube were 
assayed in duplicate, and all samples were assayed at the 
same time. Duplicates varied by less than 5%.
To observe changes in bone formation and resorption 
markers during disuse, the mean values of osteocalcin for the 
5 black bears were calculated for each time point during the 
hibernation period. These values were normalized by the 
maximum osteocalcin value during the hibernation period. 
Similar calculations were done for measurements of PICP 
(bone formation marker) and ICTP (bone resorption marker). 
The normalized values of the resorption and formation mark­
ers were plotted on the same graph to assess the temporal and 
relative magnitude changes in bone resorption and formation 
during disuse.
Using serum samples from hibernating bears obtained as 
described above, ionized calcium concentration was mea­
sured with an ion-selective electrode (Bayer Rapidlab 865, 
Leverkusen, Germany).
Using serum samples obtained as described above, PTF1 
was assayed with an ELISA kit from Immutopics Interna­
tional (San Clemente, Calif.); the intra-assay coefficient of
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Example 3variation was 4.7%. 25-OH D was assayed with an ELISA kit 
from ALPCO Diagnostics (Windham, N.Ei.); the intra-assay 
coefficient of variation was 5%. Leptinwas measured by RIA 
(Linco, St. Charles, Mo.); the intra-assay coefficient of varia­
tion was 3.4%. IGF-I was measured by acid ethanol extrac- 5 
tion RIA (Nichols Institute Diagnostics, San Juan Capistrano, 
Calif.); the intra-assay coefficient of variation was 4.3%. 
Serum osteocalcin was measured by RIA as described above.
For all the serum metabolites, the mean values (for all bears 
and all time points within a given season) were calculated for to 
each season (pre-hibernation, hibernation, and post hiberna­
tion) and compared by ANOVA. ANOVAs were followed up 
with Fisher’s PLSD tests for multiple mean comparisons. 
Natural log transformations were used to correct non-con­
stancy of variance for osteocalcin, PTF1, 25-OF1D, and IGF-I 15 
to validate the ANOVAs. Linear regressions were used to 
assess the correlations between osteocalcin and the hor­
mones. The volume of some serum samples was insufficient 
to run all assays; sample sizes for each assay are indicated 
with the results. 20
Results
The bone resorption marker (ICTP) began to increase 
immediately afterthe onset of hibernation (FIG. 3). Each data 
point is the mean value from 5 bears. After 10-20 days, the 
bone formation markers (osteocalcin and PICP) also 25 
increased and appeared to remain coupled to the increased 
resorption for the duration of hibernation. This is consistent 
with the 1-2 week histological “reversal” period between 
resorption and formation. These remodeling markers showed 
trends of increased resorption and formation throughout the 30 
hibernation period, and formation appeared to remain 
coupled and balanced with resorption. Mean osteocalcin lev­
els were higher (p<0.0001) during and after hibernation com­
pared to pre-hibernation (Table 1).
Flibernation ionized calcium levels were significantly 35 
(p=0.0062) higher than the pre-hibernation levels (Table 1). 
During remobilization following arousal from hibernation, 
ionized calcium levels did not significantly (p=0.37) increase 
relative to hibernation levels, but they remained higher 
(p=0.015) than pre-hibernation levels. 40
Osteocalcin was positively correlated with PTF1 (FIG. 2), 
but not with25-OF!D, leptin, or IGF-I. PTF1 was significantly 
higher in the post-hibernation season than in the pre-hiberna­
tion (p=0.006) and hibernation (p=0.014) seasons. The 
increase in PTF1 during hibernation relative to pre-hiberna- 45 
tion was not significant (p=0.35). 25-OF1 vitamin D did not 
show seasonal variations (p=0.64).
Serum leptin did not change during hibernation relative to 
pre-hibernation, but was significantly (p<0.004) lower during 
post-hibernation remobilization (Table 1). IGF-1 signifi- 50 
cantly (p<0.0001) decreased during hibernation relative to 
pre-hibernation and reached its highest value during remobi­
lization (Table 1).
15
PGE2 Release by MC-3T3 Osteoblasts is affected by 
Seasonal Variations in Bear Serum
To assess the effects of seasonal variations in bear serum on 
osteoblast metabolism, MC-3T3 cells were treated with bear 
serum and prostaglandin E2 (PGE2) release was quantified. 
MC-3T3 cells were grown in alpha minimum essential media 
(Invitrogen, Carlsbad, Calif.) supplemented with 10% fetal 
bovine serum (Flyclone™, Logan, Utah) and 1% penicillin- 
streptomycin solution at 37° C. in 5% C 0 2 for 24 hours. The 
media was aspirated and replaced with 10 ml of fresh media 
containing 10% bear serum collected prior to hibernation, 
during hibernation, or after hibernation. The cells were 
allowed to grow for an additional 24 hours, and then the 
media was collected and frozen at -20° C. for PGE2 analysis. 
The cells were removed from the culture dishes using 0.25% 
trypsin in EDTA, pelleted by centrifugation, and quantified 
with a trypan blue and hemocytometer.
The PGE2 levels were determined using the Biotrak™ 
PGE2 competitive enzyme immunoassay (Amersham Bio­
sciences, Piscataway, N.J.). The assay was performed in 
duplicate using 50 pi samples from all experimental media 
samples. The reaction was halted prior to endpoint determi­
nation using 1M sulfuric acid and read at 450 nm using a 
microplate reader (VERSAmax, Molecular Devices Corpo­
ration, Sunnyvale, Calif.). The duplicate optical density val­
ues were corrected for nonspecific binding and were aver­
aged, and compared to a standard curve to determine the 
amount of PGE2 in each well. These values were corrected for 
total media volume and normalized by the number of cells in 
the sample. ANOVA was used to compare the normalized 
PGE2 between the three serum groups.
The amount of PGE2, released by osteoblastic cells treated 
with bear serum in vitro, was higher for treatment with post­
hibernation serum compared to pre-hibernation serum 
(p=0.058) and hibernation serum (p=0.014) (FIG. 4). The 
PGE2 release for cells treated with the hibernation serum was 
not significantly (p=0.48) different compared to the pre-hi­
bernation serum. The seasonal changes in PGE2 release 
showed trends similar to the seasonal changes in serum IGF-I. 
P-values are for comparisons with the post-hibernation value. 
Pre-hibernation and hibernation values were not different 
from each other (p=0.48).
Example 4
Culture in Bear Serum Decreases the Ratio of Gene 
Expression of Bax to Bel-2 During Flibernation
Blood serum samples were removed from 4 female black 
bears between 2004-2005 as described above. Sample dates
TABLE 1
Mean Serum Metabolite Concentrations
Pre-hibernation Hibernation Post-hibernation
Osteocalcin (ng/ml) 16.9'’ (7.4) [15] 70.4* (43.1) [22] .u \Q W ON oo [19]
Ionized calcium (mmol/L) 0.709" (.150) [12] 0.871* (.093) [10] 0.960* (.014) P]
PTH (pg/ml) 14.6'’ (4.5) [6] 25.3" (27.3) [14] 41.4* (20.2) [9]25-OH D (nmol/ml) 16.6 (16.3) [9] 11.2 (6.2) [9] 16.0 (13.4) [9]
Leptin (ng/ml) 4.0'’ (0.7) [15] 3.8" (0.7) [22] 3.1* (0.7) [19]
IGF-I (ng/ml) 38"'“ (88) [15] 209* (52) [22] 594c (207) [19]
Mean values are given in bold, standard deviations in parentheses, and sample sizes in brackets. For a given metabolite, values with the same superscript are not significantly (p < 0.05) different. 25-OH D did not show significant seasonal differences.
US 8,987,201 B2
encompassed a pre-hibemation active period, a hibernation 
disuse period, and a post-hibernation remobilization period. 
MC-3T3 osteoblastic cells were cultured for 24 hours in 
media containing 10% bear serum, after which total RNA was 
isolated using a BioRad AquaPure RNA Isolation Kit (#732- 
6370, BioRad Laboratories, Hercules, Calif.). To generate 
cDNA, reverse transcription was performed using Super­
script II reverse transcriptase (Invitrogen, Carlsbad, Calif.), 
and 0.5 pg Obgo(dT)12-18 primer at 42° C. for 20 minutes, 
50° C. for 10 minutes and 42° C. for 1 hour in a gradient 
thermocycler (Mastercycler gradient, Eppendorf, Westbury, 
N.Y.). Primers for the pro-apoptotic protein Bax and the anti- 
apoptotic protein Bcl-2 were designed using PrimerQuest 
software (Integrated DNA Technologies, Coralville, Iowa) 
and the NCBI gene bank sequences. Semi-quantitative PCR 
was performed using RedTaq and a protocol consisting of 94° 
C. for 2 minutes, cycles of 94° C. for 30 seconds, 69.5° C. for 
30 sec and 72° C. for 1 minute, and a final extension at 72° C. 
for 5 minutes. Band intensity was quantified using the ImageJ 
software package (National Institutes of Health, Bethesda, 
Md.) and normalized to the expression of three housekeeping 
genes (Gapdh, (3-actin, cyclophillin).
ANOVA with Fisher’s Protected Least Significant Differ­
ence (PLSD) post-hoc test was used to compare the ratio of 
Bax to Bcl-2 for the three seasons (pre-hibemation, hiberna­
tion, post-hibernation). Though it did not achieve statistical 
significance (p=0.300), the Bax/Bcl-2 ratio decreased by 
approximately 42% during hibernation relative to pre-hiber­
nation. The lack of statistical significance was likely related to 
the small sample size (n=2 for each season). These data sug­
gest that semm from hibernating bears contains a biological 
molecule that decreases osteoblast apoptosis. Since endog­
enous PTH and the bone formation marker osteocalcin both 
increase during hibernation (Donahue et al., 2006; J. Exp. 
Biol., 209, 1630-8), it is possible that endogenous bear PTH 
causes a decrease in osteoblast apoptosis during hibernation, 
which in turn increases bone formation.
Example 5
Comparison of Effects of Black Bear vs. Human 
PTH 1-84 or Sub fragments Thereof on cAMP in 
Bone Cell Lines
Full-length recombinant black bear PTH (residues 1 -84) is 
produced and its effects on levels of cyclic adenosine mono­
phosphate (cAMP) concentration in bone cell lines (MC-3T3 
osteoblastic cells and MLO-Y4 osteocytic cells) are investi­
gated and compared to results obtained using recombinant 
human PTH 1-84. Equivalent experiments are conducted 
using subfragments of black bear and human PTH, the sub- 
fragments including amino acid residues 1-34, 1-36, 7-84, 
11 -84, and 41 -52 of the full-length (1 -84) mature protein. For 
some experiments, black bear and human PTH polypeptides 
are synthesized with solid-phase methods.
To determine the effect of various forms of recombinant 
black bear and human PTH polypeptides on cAMP levels in 
bone-forming cells, the cultured bone cells (MC-3T3 and 
MLO-Y4) are contacted for 10 or 30 minutes with human or 
black bear PTH full-length (i.e. amino acid residues 1-84) 
polypeptide or one of the above-listed subfragments. After 
the cell is contacted with the PTH polypeptide, cAMP con­
centration in the cell is measured using a competitive binding 
assay as described further below.
For all of the experiments using recombinant polypeptides, 
the lyophilized peptides are reconstituted to 100 uM stock
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concentrations in 1 mM acetic acid, and diluted to 10 uM 
working stock concentrations before use.
Cell Culture
MC-3T3 subclone 14 cells (ATCC, CRL-2594) andMLO- 
Y4 cells (obtained from L.F. Bonewald, University of Mis­
souri, Kansas City, Mo.) are maintained in alpha-minimum 
essential media, 1% penicillin/streptomycin, and 10% serum 
(MC-3T3: 10% fetal bovine serum (FBS), MLO-Y4: 5% FBS 
and 5% bovine calf serum), at 37° C. in 5% C 0 2. All proce­
dures described herein are repeated with independent cell 
cultures such that n=6 for all treatment combinations in each 
assay.
Effects of PTH Treatment on Intracellular cAMP Activity
MC-3T3 and MLO-Y4 cells are seeded at appropriate den­
sities (MC-3T3: 50,000 cells/cm2, MLO-Y4 15,000 cells/ 
cm2) in 6-well plates. Cells are cultured overnight to reach 
optimal confluence. The culture media is then aspirated and 
replaced with media containing either 10% serum+vehicle (1 
mM acetic acid) or 10% serum+100 nM PTH (human or bear 
1-84, or a subfragment thereof). Cells are cultured under 
these conditions for 10 or 30 minutes (Carter, P. H. et al., 
1999, J. Biol. Chem. 274(45), 31955-60; Chen, X. et al., 
2002, Am. J. Physiol. Cell Physiol. 283(5), C1432-40; 
Schiller, P. C. et al., 1999, J. Bone Miner. Res. 14(9), 1504- 
12). Following culture, the cells are trypsinized, centrifuged, 
and resuspended in lysis buffer. The suspension is incubated 
for 10 minutes and centrifuged to separate cellular debris. The 
supernatant from the cell lysate (following a 2-fold dilution) 
is assayed for cAMP concentration using a competitive bind­
ing assay (Cyclic AMP Assay #KGE002, R&D Systems, 
Minneapolis, Minn.).
With each of the polypeptides tested, there is an increase in 
cellular cAMP levels in response to the black bear PTH-based 
polypeptide.
Example 6
Comparison of Effects of Black Bear vs. Human 
PTH 1-84 or Sub fragments Thereof on Apoptosis in 
Bone Cell Lines
Full-length recombinant black bear PTH (residues 1 -84) is 
produced and its effects on apoptosis in bone cell lines (MC- 
3T3 osteoblastic cells and MLO-Y4 osteocytic cells) are 
investigated and are compared to results obtained using 
recombinant human PTH 1-84. Equivalent experiments are 
conducted using sub fragments of black bear and human PTH, 
the subfragments including amino acid residues 1-34, 1-36, 
7-84, 11-84, and 41-52 of the full-length (1-84) mature pro­
tein. For some experiments, black bear and human PTH 
polypeptides are synthesized with solid-phase methods.
To determine the relative ability of black bear and human 
PTH to prevent osteoblast and osteocyte apoptosis (under 
pro-apoptotic conditions), cells are incubated with human or 
black bear PTH 1 -84, or one of the subfragments listed above, 
for one hour. Afterwards, cells are treated for 6 hours with 
dexamethasone to induce apoptosis. Apoptosis is quantified 
with an ELISA, as described further below.
For all of the experiments using recombinant polypeptides, 
the lyophilized peptides are reconstituted to 100 uM stock 
concentrations in 1 mM acetic acid, and diluted to 10 uM 
working stock concentrations before use.
Additional experiments are performed with MC-3T3 cells 
using either 0.1% or 10% FBS. Additional experiments with 
less (0.1%) than the normal (10%) amount of FBS are run and 
the results are analyzed to determine whether there is a sig­
nificantly different response between experiments that are
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run with normal or lower levels of serum. In the experiments 
reported in this Example, the results are not affected by the 
amount of FBS that is used. Apoptosis protection studies 
show that each of the polypeptides tested reduces or prevents 
apoptosis in MC-3T3 cells.
Cell Culture
MC-3T3 subclone 14 cells (ATCC, CRL-2594) and MLO- 
Y4 cells (obtained from L. F. Bonewald, University of Mis­
souri, Kansas City, Mo.) are maintained in alpha-minimum 
essential media, 1% penicillin/streptomycin, and 10% serum 
(MC-3T3:10% fetal bovine serum (FBS), MLO-Y4: 5% FBS 
and 5% bovine calf serum), at 37° C. in 5% C 0 2. All proce­
dures described herein are repeated with independent cell 
cultures such that n=6 for all treatment combinations in each 
assay.
Effects of PTF1 Treatment on Apoptosis
MC-3T3 cells are seeded at 50,000 cells/cm2, and MLO- 
Y4 cells are seeded at 15,000 cells/cm2 in 6-well plates and 
cultured overnight to reach optimal confluence. The culture 
media is aspirated and replaced with media containing either 
10% serum+vehicle (1 mM acetic acid) or 10% serum+100 
nM PTF1 (human or bear 1-84, or a subfragment thereof). 
After a one-hour incubation (Jilkaet al., 1999; J. Clin. Invest., 
104,439-46), 10 pM dexamethasone or its vehicle (DMSO) is 
added to each well and cells are incubated for 6 hours (Bel- 
lido, T. et al., 2003, J. Biol. Chem. 278(50), 50259-72; Jilka et 
al., 1999, J. Clin. Invest., 104,439-46). The PTF1 polypeptide 
or vehicle is left in situ during apoptosis induction because the 
suppression of apoptosis by PTF1 is self-limiting (Bellido et 
al., 2003). After 6 hours, cells are trypsinized, centrifuged, 
resuspended, and counted using a hemocytometer. 50,000 
cells are removed from the suspension and placed into lysis 
buffer. The lysate supernatant (following centrifugation) is 
removed for analysis and stored at -20° C.
Apoptosis is quantified from the lysate supernatant with an 
ELISA (Cell Death Detection ELISA, #1544675, Roche 
Applied Science, Indianapolis, Ind.). This assay detects 
mono- and oligonucleosomes from fragmented cellular DNA 
in the cytoplasmic fraction of cell lysates, and therefore pro­
vides a good measure of the early and middle stages of apo­
ptosis. Briefly, samples are diluted in buffer solution and 
added to microplate wells coated with an anti-histone mouse 
monoclonal (clone Ell 1 -4) antibody. Lysate supernatant from 
the vehicle-treated cells serves as a negative control. Optical 
densities are measured at 405 nm following the addition of a 
peroxidase-conjugated anti-DNA mouse monoclonal (clone 
MCA-33) antibody, and the amount of apoptosis in each 
sample is determined relative to its corresponding negative 
control. All samples are assayed in duplicate.
Each of the polypeptides tested decreased apoptosis of the 
cells (under pro-apoptotic conditions).
Example 7
Comparison of Effects of Black Bear vs. Fhiman 
PTF1 1 -84 or Sub fragments Thereof on Gene 
Expression in Bone Cell Lines
Full-length recombinant black bear PTF1 (residues 1 -84) is 
produced and its effects on levels of gene expression in bone 
cell lines (MC-3T3 osteoblastic cells and MLO-Y4 osteo- 
cytic cells) are investigated and are compared to results 
obtained using recombinant human PTF1 1-84. Equivalent 
experiments are conducted using sub fragments of black bear 
and human PTF1, the subfragments including amino acid 
residues 1-34, 1-36,7-84, 11-84, and 41-52 of the full-length
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(1 -84) mature protein. For some experiments, black bear and 
human PTF1 polypeptides are synthesized with solid-phase 
methods.
To determine the effect of black bear and human PTF1 on 
regulation of bone matrix, transcriptional regulatory, anti­
apoptosis (Bcl-2) genes, and the pro-apoptosis gene Bax, 
cells are cultured for 1 or 3 hours with human or bear PTF1 
1-84 or a sub fragment. Gene expression is quantified with 
real-time PCR.
For all of the experiments using recombinant polypeptides, 
the lyophilized peptides are reconstituted to 100 uM stock 
concentrations in 1 mM acetic acid, and diluted to 10 uM 
working stock concentrations before use.
Additional experiments are performed with MC-3T3 cells 
using either 0.1% or 10% FBS. Additional experiments with 
less (0.1%) than the normal (10%) amount of FBS are run and 
the results are analyzed to determine whether there is a sig­
nificantly different response between experiments that are 
run with normal or lower levels of serum. In the experiments 
reported in this Example, the results are not affected by the 
amount of FBS that is used. Real-time PCR is used to assess 
gene expression levels at 1 - and 3-hour time points following 
addition of the polypeptide, showing in particular that black 
bearPTFl l-34upregulates gene expression in MC-3T3 cells. 
Cell Culture
MC-3T3 subclone 14 cells (ATCC, CRL-2594) andMLO- 
Y4 cells (obtained from L. F. Bonewald, University of Mis­
souri, Kansas City, Mo.) are maintained in alpha-minimum 
essential media, 1% penicillin/streptomycin, and 10% serum 
(MC-3T3: 10% fetal bovine serum (FBS), MLO-Y4: 5% FBS 
and 5% bovine calf serum), at 37° C. in 5% C 0 2. All proce­
dures described herein are repeated with independent cell 
cultures such that n=6 for all treatment combinations in each 
assay.
Effects of PTF1 Treatment on Gene Expression
MC-3T3 cells are seeded at a density of 50,000 cells/cm2, 
and MLO-Y4 cells are seeded at a density of 15,000 cells/cm2 
in 6-well plates and cultured overnight to reach optimal con­
fluence. The culture media are aspirated and replaced with 
media containing either 10% serum+vehicle (1 mM acetic 
acid) or 10% serum+100 nM PTF1 (human or bear 1-84, or a 
sub fragment as listed above). Cells are cultured under these 
conditions for 1 or 3 hours; these time points correspond with 
PTFl-induced upregulation of c-fos and osteocalcin (Jiang et 
a l, 2004, J. Biol. Chem, 279, 5329-37; Chen et a l, 2002). 
Total RNA is isolated using the SV Total RNA Isolation 
System (Promega, Madison, Wis.).
Reverse transcription to generate cDNA is performed 
using Superscript II reverse transcriptase (Invitrogen, Carls­
bad, Calif.), and 0.5 pg Ohgo(dT)12-18 primer at 42° C. for 
20 minutes, 50° C. for 10 minutes and 42° C. for 1 hour in a 
gradient thermocycler (Mastercycler gradient, Eppendorf, 
Westbury, N.Y.). Primers for all genes of interest (osteocalcin, 
osteopontin, type I collagen, c-fos, Runx2, Bax, Bcl-2, 
SOST) and housekeeping genes (Gapdh, (3-actin, cyclophil- 
lin) are designed using PrimerQuest software (Integrated 
DNA Technologies, Coralville, Iowa) and the NCBI gene 
bank sequences, and the PCR conditions are optimized using 
RNA from MC-3T3 and MLO-Y4 cells. Real-time PCR is 
performed using the Mx3000P real-time PCR system (Strat- 
agene, La Jolla, Calif.). The protocol involves a hot start at 
95° C. for 10 minutes followed by 40 cycles of 95° C. for 30 
seconds (denaturation), 69° C. for 1 minute (annealing) and 
72° C. for 1 minute (extension). The exception to this protocol 
is for c-fos, which has an annealing temperature of 66° C. 
Each 25 pi reaction contains lx  Absolute™ qPCR SYBR® 
green mix (ABgene, Rochester, N.Y.), 0.1 pM forward and
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reverse primer, and 2.5 ng total RNA equivalent cDNA tem­
plate. Gene expression is determined using the relative stan­
dard curve method normalized to the geometric mean of the 
three housekeeping genes. All samples are measured in dupli­
cate, and any samples with a coefficient of variation (CV) 
greater than 10% are reanalyzed.
The polypeptides cause an upregulation of bone matrix, 
transcriptional regulatory, and transcriptional activator genes, 
and a decrease in the expression ratio of Bax/Bcl-2.
Example 8
Comparison of the Effects of Black Bear Serum 
from Different Seasons on Bone Cell Apoptosis and 
Gene Expression, and Correlation with Serum Levels 
of PTE1 and Osteocalcin
Blood samples are collected from at least 3 different female 
black bears (Ursus americanus pallas) held in the Virginia 
Tech Center for Bear Research between 2004 and 2005. 
Serum from additional black bears is collected in subsequent 
years. The Virginia Polytechnic Institute and State University 
Animal Care Committee approved all bear handling proto­
cols (#98-069-F&WS). The bears are anesthetized with a 2:1 
mixture of ketamine (100-mg/ml):xylazine (100-mg/ml); the 
dosage is 1 cc of the mixture per 45.5 kg of body mass. Blood 
samples are drawn from the femoral vein while the bears are 
anesthetized, and the samples are transported to the labora­
tory in an ice-packed cooler. Immediately on return to the 
laboratory, the blood is centrifuged to isolate the serum, 
which is then frozen at -20° C. Blood samples are collected 
from each bear every 10 days from the beginning of October 
until the end of May. Elibernation begins in early January and 
ends in early April. Thus, the collection dates encompass an 
active pre-hibernation period, a disuse hibernation period, 
and an active post-hibernation remobilization period.
Aliquots of 10 pi of bear serum are assayed in duplicate for 
osteocalcin concentration by radioimmunoassay (Patterson- 
Alien et al., 1982; Anal. Biochem., 120, 1-7). This assay has 
previously been validated for bears (Donahue et al., 2006; J. 
Exp. Biol., 209, 1630-8). The antibody is guinea-pig anti-rat 
osteocalcin and tracer is 125I-labeled rat osteocalcin. Aliquots 
of 100 pi of bear serum are assayed in duplicate for PTE1 
concentration (Donahue et al., 2006; J. Exp. Biol., 209,1630- 
8) with an ELISA (Porcine Intact PTH ELISA Kit, #60-3305, 
Immutopics, Inc., San Clemente, Calif.). This assay binds the 
39-84 region of PTH, and requires the 13-34 region of PTH to 
colorimetrically report PTH concentration. Thus, it provides 
a good measure of intact (1-84) PTH concentration as well as 
C-terminal subfragments 7-84 and 11-84. This ELISA has 
been shown to cross-react with bear PTH (Donahue et al., 
2006; J. Exp. Biol., 209, 1630-8), and has 100% cross-reac­
tivity with human PTH. To validate this assay for black bears, 
samples of culture media containing 10 nM recombinant 
black bear or human PTH 1 -84 are assayed in duplicate. The 
known concentration of the PTH samples is compared to the 
measured concentration determined from the assay’s stan­
dard curve. Any potential difference in cross-reactivity deter­
mined from these samples is used as a correction for endog­
enous black bear PTH concentration in the black bear serum 
samples.
The procedures described above for recombinant black 
bear PTH apoptosis and gene expression cell culture experi­
ments with cultured bone-type cells are repeated, substituting 
the 100 nM recombinant PTH-containing media with culture 
media containing 10% black bear serum (from pre-hiberna­
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tion, hibernation, or post-hibernation periods). The serum 
volumes are calculated following the PTH ELISA described 
above.
Serum from the hibernation and post-hibernation seasons 
causes a greater prevention of apoptosis compared to pre­
hibernation serum, because PTH is higher during hibernation 
and post-hibernation than in pre-hibernation serum. Endog­
enous serum PTH concentrations are inversely related to apo­
ptosis levels, in that higher serum PTH levels correspond to 
lower rates of apoptosis, i.e. serum PTH concentrations are 
negatively correlated with apoptosis levels.
Example 9
In Vivo Testing of Bear PTH
Black bear PTH, either full-length (1 -84) or one of several 
functional subfragments thereof (1-34; 1-36; 7-84; 11-84; 
41-52), are tested in vivo for anabolic stimulation of bone 
cells compared to an equivalent human PTH or subfragment. 
Each of the PTH polypeptides is synthesized and suspended 
in a pharmaceutically-appropriate carrier for subcutaneous 
injection. Full-length PTH or a functional fragment thereof, 
from either black bear or human, is administered to mice at a 
dose of 40 pg/kg body weight daily for 7 weeks. Black bear 
PTH or a functional fragment thereof cause greater increases 
in bone strength, mass, and mineral content than the equiva­
lent human PTH polypeptide.
Example 10
Use of Bear PTH as Prophylactic Agent to Reduce or 
Prevent Bone Loss
Osteoporosis is induced in mice by hindlimb suspension (a 
disuse model of osteoporosis) and by ovariectomy (a post­
menopausal model of osteoporosis). After the hindlimb sus­
pension begins or the ovariectomy is completed, the mouse is 
given regular doses of black bear PTH or a functional frag­
ment thereof. The mice treated with black bear PTH or func­
tional fragments thereof show less bone loss than untreated 
mice.
Example 11
Bear and human PTH 1-34 both upregulate gene 
expression of osteocalcin, but only bear PTH 1-34 
decreases the expression ratio of Bax/Bcl-2
MC-3T3 cells were incubated in vehicle or 100 nM syn­
thetic bear or human PTH 1-34 for 3 or 6 hours (n=2 or 4). 
Total RNA was isolated, and cDNA was generated with 
reverse transcription. Primers for the bone matrix proteins 
type I collagen and osteocalcin, the pro-apoptotic protein 
Bax, the anti-apoptotic protein Bcl-2, and the housekeeping 
genes Gapdh, (3-actin, and cyclophillin were designed using 
PrimerQuest software (Integrated DNA Technologies, Cor- 
alville, Iowa). Real-time PCR was performed using the 
Mx3000Preal-time PCR system (Stratagene, LaJolla, Calif.). 
All samples were measured in duplicate. Gene expression 
was determined using the relative standard curve method 
normalized to the geometric mean of the three housekeeping 
genes (Gapdh, (3-actin, and cyclophillin). Apoptosis-related 
genes were analyzed as the expression ratio of Bax/Bcl-2, 
since a decrease in this ratio is associated with decreased 
apoptosis in vitro.
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Culture in human or bear PTH 1-34 for 6 hours did not 
affect expression of type I collagen but substantially upregu- 
lated the expression of osteocalcin compared to the vehicle 
control (FIG. 6). There were no significant differences 
between human and bear PTH (p>0.09).
Culture in bear PTH 1-34 for 3 hours decreased the expres­
sion ratio of Bax/Bcl-2, suggesting decreased apoptosis, but 
culture in human PTH 1-34 for 3 hours increased the ratio, 
suggesting increased apoptosis (FIG. 7). The difference 
between bear and human PTH was statistically significant 
(p=0.047).
Example 12
In Vivo Rat OVX Dose Response Study
Ninety female, 3-month old Sprague-Dawley rats were 
obtained. Eighty (80) of the rats were ovariectomized (OVX) 
and ten (10) underwent a sham OVX procedure (sham OVX) 
in which the ovaries were left in the animal. The OVX animals 
were randomly assigned into groups of ten for further experi­
ments.
Following the actual or sham OVX procedure, all animals 
were untreated for 6 weeks to allow bone loss. After the 6 
week period of bone loss, groups of animals were injected for 
a six- or eight-week period (daily for five days per week) with 
vehicle (saline) or 3,10, or 30 pg/kg bear or human PTH 1-34. 
The current dose of PTH1-34 for humans is approximately 
0.3 pg/kg while a dose as low as 5 pg/kg has been shown to be 
carcinogenic in rats (Tashjian et ah, J. Bone Mineral Res. 
23(6): 803-811 (2008)). The sham OVX group as well as one 
group of actual OVX rats were euthanized at six weeks while 
the remaining animals were euthanized at fourteen weeks 
following the OVX procedure. Samples were obtained from 
the euthanized animals for further analysis.
Three-dimensional images of bones were obtained using 
micro-computed tomography (pCT). The three-dimensional 
images were then used to quantify bone parameters, as 
explained below. The measurements were conducted on a 1.6 
mm-thick region that begins at a position 2 mm from the 
growth plate (FIG. 8). Bone samples were obtained and ana­
lyzed from sham (FIG. 9A, “Sham OVX 6 weeks”) and actual 
(FIG. 9B, “OVX 6 weeks”) OVX rats that were euthanized at 
six weeks after the procedure, as well as a group of actual 
OVX rats that were euthanized at fourteen weeks after the 
procedure (FIG. 9C, “OVX 14 weeks”). The rats in the OVX 
14 group were given injections of vehicle (saline) for 8 weeks 
following the 6 week bone loss period, in parallel with the 
PTH1-34 injections for eight weeks (FIGS. 9D, 9E, and 9F). 
The samples shown in FIGS. 9D, 9E, and 9F were obtained 
from rats that were injected for eight weeks following the 6 
week bone loss period, with 3, 10, or 30 pg/kg black bear 
PTH1-34 (“bbPTH”), respectively.
As can be seen in the images, bones from rats at 6 weeks 
(FIG. 9B) and 14 weeks (FIG. 9C) following OVX surgery 
demonstrated noticeable amounts of bone loss compared to 
bones from sham OVX (FIG. 9A) and bbPTH-treated rats 
(FIGS. 9D-9F). Rats treated with black bear PTH1-34 had 
dose-dependent greater bone mass at each of the dosage lev­
els (FIGS. 9D-9F) compared to the OVX rats that received 
injections of vehicle (saline) only (FIG. 9C).
Differences in bone parameters between the sham OVX, 
OVX, and PTH-treated rats were quantified. FIG. 10 shows 
bone volume as a fraction of total volume (BV/TV) for the 
various treatment groups. The baseline level of bone volume 
fraction in the presence of ovaries (“sham baseline,” light 
diamond) and the baseline level six weeks after loss of ovaries
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and in the absence of PTH treatment (“OVX baseline,” dark 
diamond) are shown at the left, in the column labeled “6 
weeks.” Treatment of OVX rats with vehicle (saline) alone for 
fourteen weeks (“OVX vehicle,” triangle) led to a further 
decline in bone volume fraction. Treatment of OVX rats with 
human (“hPTHl-34,” squares) or black bear (“bbPTHl-34,” 
circles) PTH1-34 increased bone volume fraction in a dose- 
dependent manner. At the highest dose of 30 pg/kg, treatment 
with human PTH led to a significantly (p<0.05) greater bone 
volume fraction than treatment with bear PTH or with vehicle 
(saline) alone. Treatment with human PTH produced a sig­
nificantly (p<0.05) greater bone volume fraction than treat­
ment with vehicle (saline) alone at all three levels tested, 
while bear PTH produced a significantly (p<0.05) greater 
bone volume fraction than treatment with vehicle (saline) 
alone at 10 pg/kg and 30 pg/kg.
Similarly, bone mineral apparent density was determined 
for each of the samples (FIG. 11) and is shown as milligrams 
hydroxyapatite per cubic centimeter (“App.Dn 
(mgHA/ccm)”). The bone mineral apparent density was sig­
nificantly higher (p<0.05) for bones of OVX rats treated with 
3,10, or 30 pg/kg hPTH or bbPTH than for bones of OVX rats 
treated with vehicle (saline) alone. The bone mineral apparent 
density for OVX rats treated with 30 pg/kg hPTH was sig­
nificantly higher (p<0.05) than OVX rats treated with 30 
pg/kg bbPTH.
The number and thickness of trabecular struts were also 
determined for bones from sham OVX, OVX without PTH 
treatment, and PTH-treated OVX rats (FIG. 12). The symbols 
show the trabecular number per millimeter (“Tb.N 
(mnT-1)”) for sham OVX rats (“sham baseline,” light dia­
monds), OVX rats treated with vehicle (saline) alone and 
euthanized at six weeks (“OVX baseline,” dark diamonds), 
OVX rats treated with vehicle (saline) alone for eight weeks 
and euthanized at fourteen weeks (“OVX baseline,” dark 
diamonds), and OVX rats treated with 3, 10, or 30 pg/kg 
human (“hPTHl-34,” squares) or bear (“bbPTHl-34,” 
circles) PTH1-34 (FIG. 12).
The average thickness of the trabecular struts was also 
determined (FIG. 13). Treatment with either bear or human 
PTH significantly (p<0.05) increased the average thickness of 
the trabecular struts (“Tb.Th (mm)”) compared to vehicle- 
treated controls.
Black bear PTH1-34 showed a trend of greater trabecular 
bone mineralization (“M.Dn (mgHA/ccm)”; FIG. 14) with 
increasing dose compared to human PTH1-34. Treatment of 
OVX rats with either bear (“bbPTHl-34,” circles) or human 
(“hPTHl-34,” squares) PTH1-34 produced significantly 
(p<0.05) greater trabecular bone mineralization than OVX 
rats treated with vehicle (saline) alone.
Human PTH1-34 (“hPTH,” squares) is better than bear 
PTH1-34 (“bPTH,” circles) at increasing tibial cortical bone 
volume (“BV(mnT2),” FIG. 15). Overall, however, changes 
in the bone cortical region were moderate relative to the 
changes observed in bone trabeculae.
Tibial cortical porosity in bones of OVX rats was observed 
to be significantly (p<0.05) decreased when the rats were 
treated with middle (10 pg/kg) and higher doses (30 pg/kg) of 
either bear (“bbPTFH-34,” circles) or human (“hPTHl-34,” 
squares) PTH1-34 relative to bones from OVX rats treated 
with vehicle (saline) alone (FIG. 16). However, only higher 
doses (30 pg/kg) of human or bear PTH1-34 produced sig­
nificant (p<0.05) increases in femoral cortical bone strength 
relative to vehicle-treated controls (FIG. 17).
An additional benefit that black bear PTH1 -34 may confer 
over human PTH1-34 is lower serum calcium. Hypercalce­
mia (elevated serum calcium) is a side effect of PTH treat -
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ment in humans. In the present experiments, serum calcium 
levels were seen to be lower in rats treated with bear PTH 1-34 
compared to human PTH1-34, although the results are not 
significant at the p<0.05 level. However, statistical analyses 
predict that serum calcium concentrations would be signifi­
cantly (p<0.05) lower in black bear PTH1-34 treated rats if 
the sample size were doubled. Thus, black bear PTH1-34 
treatment may reduce the incidence of this side effect.
The experiments show that black bear PTH1 -34 is equally 
effective as human PTH1 -34 at producing dramatic increases 
in trabecular bone formation. Human PTH1-34 was observed 
to be more effective than bear PTH1-34 for several param­
eters at the highest dose (30 pg/kg), although this is 100 times 
higher than doses given to humans. However, at lower and 
more clinically-relevant doses, bear PTH1-34 was as effec­
tive as human PTH1-34 at increasing important parameters 
related to reducing bone fracture likelihood.
Example 13
Bear PTH1-34 and Bear PTH1-84 Reduce Caspase-3 
Activity in Cultured Mouse Osteoblasts
Cell Culture
MC3T3 subclone 4 cells (ATCC, CRL-2593) were main­
tained in standard culture media (89% alpha-minimum essen­
tial media, 1% penicillin/streptomycin, and 10% FBS) at 37° 
C. in 5% C02. Cells were not used beyond passage 30.
PTH Attenuation of Serum-Starvation Induced Apoptosis
MC3T3 cells were seeded at a density o f20,000 cells/well 
in 96-well plates and allowed to attach overnight. Culture 
media was then aspirated and replaced with 100 pi of culture 
media containing 10% FBS and either vehicle (PBS) or PTH 
(10-100 nM) for one hour, after which media was aspirated 
and cells were washed with PBS to remove residual serum. To 
induce apoptosis, cells were incubated in control or serum- 
free media for 6 hours. Replacement media contained 89% 
alpha-minimum essential media, 1 % penicillin/streptomycin, 
and either 10% FBS (control media) or 0% FBS (starvation 
media). After starvation, media was aspirated, cells were 
washed with PBS, and 50 pi of fresh PBS was added to each 
well. Caspase-3/7 activity was determined by cleavage of a 
DEVD substrate (Caspase-Glo 3/7 Assay, #G8093, Promega 
Corporation). Measured luminescence values were fit to a 
standard curve prepared with known concentrations of 
recombinant human caspase-3 (#SE-169, BIOMOL 
Research Laboratories Inc.). Five wells of each treatment 
were run per 96-well plate, and procedures were repeated on 
a minimum of 10 plates.
Statistics
Attenuation of caspase-3/7 activation was compared 
between peptide, vehicle, and control-treated samples with 
ANOVA with Fisher’s PLSD, blocking by experiment repli­
cation. Caspase-3/7 activity values were normalized to the 
control media (unstarved cells) caspase-3/7 level within each 
replication, and analysis of covariance (ANCOVA) was used 
to compare the dose response behavior of the peptides, treat­
ing concentration as the covariate.
Serum starvation significantly (p<0.0001) increased 
caspase-3/7 activity (an early indicator of apoptosis) in the 
vehicle and PTH-pretreated samples compared to non- 
starved cells in this experiment (FIG. 19). All PTH pretreat­
ments significantly (p<0.0001) lowered caspase-3/7 activity 
compared to vehicle-treated cells. PTH-induced reduction in 
caspase-3/7 activity did not demonstrate a dose-dependent 
behavior (p=0.890), therefore, all concentrations were pooled 
within groups for between group comparisons. Of the four
25
peptide groups, bbPTH 1-34 demonstrated the greatest 
attenuation of serum starvation-induced apoptosis; mean 
caspase-3/7 activity in the bbPTH 1-34 group were signifi­
cantly lower than the hPTH 1-34 group (p=0.006) and either 
PTH 1-84 group (p<0.018) (FIG. 19). In contrast, the differ­
ence in caspase-3/7 activity between the bbPTH 1-84 and 
hPTH 1-84 groups approached significance (p=0.090) with 
hPTH 1-84 indicating lower levels of apoptosis (FIG. 19).
Example 14
In Vivo Effects of Bear PTH1-34 and Bear PTH1-84 
in Male Swiss-Webster Mice
Animals
All handling procedures and experiments were approved 
by the Michigan Technological University Institutional Ani­
mal Care and Use Committees. Male Swiss-Webster mice 
were obtained from a commercial breeder (Harlan, India­
napolis, Ind.). All animals were maintained on a 12-h light/ 
12-h dark cycle, and were permitted free access to water and 
food containing 0.95% calcium (Purina Rodent Diet #5001).
In the first experiment, 11 wk old mice received daily (5 
days/week) subcutaneous injections of 2.5 nmol/kg PTH 
1-34 (hPTH 1-34 or bbPTH 1-34) or acidic saline vehicle 
(0.15 MNaCl+0.001 NHC1) for 8 weeks (n=10mice/group). 
In the second experiment, 12 wk old mice received daily (5 
days/week) subcutaneous injections of 2.5 nmol/kg PTH 
1 -84 (hPTH 1 -84 or bbPTH 1 -84) or acidic saline vehicle for 
8 weeks (n=10 mice/group). All PTH- and vehicle-treated 
animals received subcutaneous injections of calcein at a dos­
age of 10 mg/kg on days 12 and 3 before death to label 
mineralizing bone surfaces. Twenty-four hours following the 
last treatment injection, mice were sacrificed by carbon diox­
ide asphyxiation. Right femurs were fixed in 10% neutral 
buffered formalin. Left femurs were wrapped in 0.15M saline 
soaked gauze and stored at -20 deg C. Left tibias were stored 
in 70% ethanol at 4 deg C.
Trabecular Bone Structure and Mineralization in the Proxi­
mal Tibia
Trabecular bone architecture and mineralization were 
evaluated in the left proximal tibial metaphysis (0.7 mm distal 
to the growth plate) using micro-computed tomography. 
Tibias from experiment 1 were scanned on a pCT35 scanner 
(Scanco Medical AG, Basserdorf, Switzerland) at 3.5 pm 
(high) resolution. Tibias from experiment 2 were scanned on 
a pCT40 scanner (Scanco Medical AG, Basserdorf, Switzer­
land) at 7 pm (high) resolution. Bones were scanned in 70% 
ethanol. Trabecular bone volume fraction (BV/TV, %), trabe­
cular number (Tb.N, mm"1), trabecular thickness (Tb.Th, m), 
trabecular separation (Tb.Sp, m), trabecular apparent mineral 
density (App.Mn.Dn, mgHA/cm3) and trabecular tissue min­
eral density (Mat.Mn.Dn, mgHA/cm3) were computed using 
the manufacturer’s software.
Cortical Bone Mechanical Properties of the Femur
Left femurs were loaded to failure in 3 -point bending on an 
Instron mechanical testing system (Model #8872, Canton, 
Mass.) at a rate of 1 mm/min. Bones were oriented with the 
anterior surface in compression. The lower testing fixture 
supports were separated by a span of 10 mm, and all fixtures 
had rounded contact points (radius=l mm) to prevent local­
ized stress concentrations in the bone. Ultimate load was 
calculated using the load-deformation data from testing. 
Cortical Bone Mineral Content, Geometrical Properties, and 
Dynamic Histomorphometry
Following the bending test, the left femoral diaphyses were 
ashed in a furnace to determine mineral content (ash fraction).
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Right femoral diaphy ses were embedded in methyl methacry­
late and sectioned with a diamond saw to expose the midshaft 
cross-section. Images of the midshaft cross-sections were 
captured using a digital camera (Spot Insight QE, Diagnostic 
Instruments Inc., Sterling Heights, Mich.), and Scion Image 5 
analysis software (Scion Corporation, Frederick, Md.) was 
used to calculate the periosteal area (Ps.Ar), cortical area 
(Ct.Ar), and endosteal area (Es.Ar) for each sample. Cortical 
bone thickness (Ct.Th) was calculated in 0.1 mm increments 
for each anatomical quadrant and for the entire cross-section to 
using image analysis software (Bioquant Osteo, Nashville, 
Term.). Thin sections from the midshaft of the right femur 
were ground to a thickness of 50 pm and mounted on glass 
slides. Images of calcein labels were captured at lOOx mag­
nification and periosteal and endosteal mineral apposition 15 
rates (Ps.MAR and Es.MAR, respectively) and mineralizing 
surfaces (Ps.MS/BS and Es.MS/MS) were quantified (Bio­
quant) for each femur.
In Vivo Experiments Statistics
All bone geometrical, architectural, and mineral properties 20  
were normalized by body mass to account for potential varia­
tion in animal size (31-33). Trabecular bone properties quan­
tified by micro-computed tomography were compared by 
ANOVA between vehicle, bear, and human PTH-treated mice 
within each study (PTH 1-34 or PTH 1-84). The microCT 25 
parameters were not directly compared between the PTH 
1-34 and PTH 1 -84 studies because analyses were conducted 
on different microCT machines. For all other bone properties,
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all six experimental groups (from both the PTH 1-34 and PTH 
1-84 studies) were compared with ANOVA and Fisher’s 
PLSD. A significance of p<0.05 was used for all comparisons. 
Results
Trabecular Bone Structure and Mineralization in the Proxi­
mal Tibia
Trabecular bone microCT data are presented in Tables 2 
and 3. There were no significant differences between experi­
mental groups in the PTH 1-34 study, although trabecular 
bone material density tended to be lowest in mice treated with 
bbPTH 1-34 (Table 2). In contrast, bone volume fraction was 
greater in the proximal tibia of mice treated with bbPTH 1-84 
compared to hPTH 1-84 (Table 3). Differences between the 
effects of bbPTH 1 -84 and hPTH 1 -84 on bone volume frac­
tion were significant (p=0.013), with bbPTH being the more 
efficacious therapy. The increase in bone volume fraction in 
the bbPTH 1 -84 treated mice was likely influenced by trabe­
cular thickness since trabecular thickness tended to be greater 
in mice treated with bbPTH 1 -84 compared to mice treated 
with hPTH 1-84 (p=0.089). Trabecular number and trabecu­
lar separation were not significantly different between groups 
in the PTH 1 -84 study (Table 3). Trabecular apparent mineral 
density was highest in mice treated with bbPTH 1-84 com­
pared to other treatments; the difference in the effects of 
bbPTH 1-84 and hPTH 1-84 was statistically significant 
(p=0.019) (Table 3). Trabecular material mineral density 
tended to be highest in mice treated with bbPTH 1-84 (Table 
3).
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TABLE 1
Trabecular bone architectural properties and mineral density
in the proximal tibia of mice from the PTH 1-34 study
ANOVA
Bone Property Vehicle hPTH 1-34 bbPTH 1-34 p-value
BV/TV (%/kg) 1.46 (0.68) 1.35 (0.76) 1.34 (0.35) 0.883
Tb. N (l/mm*kg) 115.2 (27.2) 105.0 (26.8) 107.4 (19.1) 0.629
Tb. Th (mm/kg) 0.96 (0.11) 1.05 (0.10) 1.02 (0.21) 0.446
Tb. Sp (mm/kg) 9.17 (2.48) 9.57 (2.29) 8.76 (2.39) 0.752
App. Mn. Dn
(mgHA/(cm3*kg))
1829 (994) 1783 (1052) 1720 (537) 0.963
Mat. Mn. Dn. 32563 (2743) 31281 (1957) 30457 (1412) 0.099
(mgHA/(cm3*kg))
Standard deviations are shown in parentheses.
See text for explanations of abbreviations.
TABLE 2
Trabecular bone architectural properties and mineral density
in the proximal tibia of mice from the PTH 1-84 study.
ANOVA
Bone Property Vehicle hPTH 1-84 bbPTH 1-84 p-value
BV/TV (%/kg) 1.61 (0.75) “• b 1.34 (0.83) b 2.26 (0.72) “ 0.038
Tb. N (l/mm*kg) 97.0 (21.9) 98.7 (20.1) 113.8 (24.3) 0.193
Tb. Th (mm/kg) 1.22 (0.08) 1.26 (0.18) 1.38 (0.17) 0.055
Tb. Sp (mm/kg) 8.94 (2.35) 9.57 (2.04) 8.47 (2.36) 0.558
App. Mn. Dn
(mgHA/(cm3*kg))
2729 (1029) “• b 2513 b (1118) 3665 (935) “ 0.043
Mat. Mn. Dn.
(mgHA/(cm3*kg))
28667 (1534) 29810 (2317) 30552 (1374) 0.077
Standard deviations are shown in parentheses.
Different superscripts indicate significant differences (p < 0.05) between groups. 
See text for explanations of abbreviations.
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Cortical Bone Mechanical Properties and Ash Fraction of 
the Femur
Ultimate load of the femur was increased by peptide treat­
ment (+3% to +15% compared to vehicle-treated mice) (FIG. 
29). The increase in bone strength was significantly 
(p=0.032) greater in mice treated with bbPTFl 1 -84 compared 
to hPTFl 1 -84, but was not different (p=0.819) between mice 
treated with bbPTFl 1-34 andhPTFl 1-34. Bone mineral con­
tent (ash fraction) was not different between the treatment 
groups (p=0.180) (data not shown).
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Cortical Bone Geometrical Properties in the Femur 
Bone periosteal area was highest in vehicle treated mice 
from the PTF1 1 -34 study and lowest in vehicle-treated mice 
from the PTF11 -84 study (Table 3). Mice treated with bbPTFl 
5 1 -84, but not hPTFl 1 -84, had significantly greater values for 
periosteal area compared to vehicle-treated mice, but mice 
treated with both PTF1 1-34 peptides had lower values for 
periosteal area compared to vehicle treated mice (Table 3). 
Neither cortical bone area nor endosteal area were different 
10 between treatment groups (p>0.136). Cortical bone thickness 
was greater in mice from the PTF11-84 study compared to the 
PTF11-34 study, but there were no other differences between 
treatment groups (Table 3).
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TABLE 3
Cortical bone geometrical properties in the femoral midshaft of PTH-treated mice.
Bone
property
Vehicle
(1-34)
hPTH
1-34
bbPTH
1-34
Vehicle
(1-84)
hPTH
1-84
bbPTH
1-84
ANOVA
p-value
Ps.Ar
(mm2/k2)
60.5 (7.5)" 55.3 (5 .2 )b-c 56.0 (3 .6 )b-c 53.7 (3.6)c 54.6 (A A )b-c 58.3 (5.0)“-* 0.042
Ct.Ar
(mm2/k2)
31.3 (2.9) 30.7 (3.0) 31.7 (3.5) 28.9 (2.9) 29.0 (3.7) 31.7 (3.7) 0.194
Es.Ar
(mm2/k2)
29.2 (7.5) 24.7 (3.7) 24.3 (2.0) 24.8 (2.9) 25.6 (3.3) 26.6 (4.6) 0.136
Ct.Th 1.97 (0.19)4 2.22 (0.20)4 2.14 (0 .2 6 )b 3.29 (0.40)" 3.41 (0.59)" 3.56 (0.42)" <0.0001
(mm/kg)
Standard deviations are shown in parentheses.
Different superscripts indicate significant differences (p < 0.05) between groups. 
See text for explanations of abbreviations.
Cortical Bone Dynamic Flistomorphometry in the Femur 
There were no significant differences in periosteal or 
endosteal mineralizing surface or mineral apposition rate 
between treatment groups (p>0.236) (Table 4).
TABLE 4
Cortical bone dynamic histomorphometry in the femoral midshaft of PTH-treated mice.
Bone
property
Vehicle
(1-34)
hPTH
1-34
bbPTH 1- 
34
Vehicle
(1-84)
hPTH
1-84
bbPTH
1-84
ANOVA
p-value
Periosteal 20.9 (13.8) 24.0 (13.8) 28.9 (13.6) 22.2 (10.6) 20.2 (16.7) 31.3 (22.5) 0.526
MS/BS
Endosteal 20.4 (16.7) 39.3 (17.7) 31.2 (25.9) 27.8 (14.3) 32.1 (19.4) 24.5 (17.2) 0.317
MS/BS
Periosteal 0.44 (0.23) 0.53 (0.21) 0.64 (0.21) 0.69 (0.34) 0.60 (0.40) 0.62 (0.33) 0.490
MAR
Endosteal 0.47 (0.20) 0.56 (0.18) 0.63 (0.26) 0.81 (0.25) 0.62 Q.39) 0.59 (0.42) 0.236
MAR
Standard deviations are shown in parentheses.
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CONCLUSIONS
These Data indicate that bbPTH 1-34 is more anti-apop- 
totic than hPTH 1-34 and hPTH 1-84 in vitro, however, 
bbPTH 1-84 increases bone volume and strength in mice 
more than hPTH peptides. This suggests bbPTH has potential 
as a new anabolic therapy for osteoporosis.
The hPTH peptides in these studies did not produce an 
increase in trabecular bone mass compared to vehicle treat­
ment (Tables 1 and 2), likely because of the relatively low 
peptide dosage administered to the mice. Short-term in vivo 
studies of PTH’s anabolic effects in mice typically use pep­
tide dosages >10 nmol/kg to produce a large increase in bone 
formation and bone mass over a short period of time. In 
previous studies, lower peptide dosages are less osteogenic in 
short-term studies; daily injections of 1 nmol/kg hPTH 1-34 
for 6 weeks did not affect trabecular thickness (Tb.Th) or 
mineral apposition rates (MAR) in the proximal tibia of male 
mice, whereas a higher molar dosage of hPTH (-10 nmol/kg) 
increased these properties. See Sakai et al. (1999) J Bone 
Miner Res 14(10): 1691-9. A dosage of 2.5 nmol/kg was used 
in our studies because it is the lowest peptide dosage shown to 
increase osteoblast number and decrease osteoblast apoptosis 
in trabecular bone secondary spongiosa in mice (see Bellido 
et al. (2003) J Biol Chem 278(50): 50259-72), and it is closer 
to a clinical dosage (20 pg/day, approximately 0.07 nmol/kg 
for a 70 kg patient) compared to PTH dosages used in other 
short-term in vivo studies. Although hPTH peptides did not 
increase trabecular bone mass at 2.5 nmol/kg, mice treated 
with the same dosage of bbPTH 1-84 showed improvement in 
trabecular bone properties (Table 2) and cortical bone 
strength (FIG. 29) compared to hPTH 1-84. Trabecular thick­
ness tended to be elevated in mice treated with bbPTH 1-84 
(Table 2). Importantly, trabecular bone volume fraction and 
apparent mineral density were only significantly increased 
over vehicle treatment by bbPTH 1 -84 (Table 2). Most of the 
peptide analogs investigated tended to increased femoral ulti­
mate load, but the increase over vehicle treatment was only 
statistically significant for bbPTH 1-84 (FIG. 29). Taken 
together, these findings raise the possibility that bbPTH may 
be an effective osteogenic therapy at a lower dose than hPTH.
All PTH peptides used in the current study attenuated 
apoptotic signaling induced by serum starvation in vitro (FIG. 
19). bbPTH 1-34 reduced apoptotic signaling in pre-osteo- 
blastic cells more than human PTH (FIG. 19). Recently, we 
found similar results with preliminary studies in human fetal 
osteoblasts (hFOB). Serum starvation for 24 hours increased 
cell death in hFOB (confirmed via trypan blue staining), but 
pretreatment of hFOB cells with 100 nM PTH 1-34 or 1-84 
for 1 hour before starvation reduced percent cell death (per­
centage change in cell death compared to vehicle pretreat­
ment, hPTH 1-34: -18%, bbPTH 1-34: -25%, hPTH 1-84: 
-17%, bbPTH 1-84: -21%; p<0.0001; data not shown). The 
enhanced anti-apoptotic effects of bbPTH 1-34 led to the 
expectation that bbPTH 1-34 would be the most potent osteo­
genic agent in vivo. However, although bbPTH 1 -84 was less 
anti-apoptotic than bbPTH 1-34 and hPTH 1 -34 in vitro (FIG. 
19) it caused the greatest increases in cortical and trabecular 
bone mass in the in vivo studies (Table 1, Table 2).
The disparity between the in vitro and in vivo studies 
cannot be reconciled at present. Reducing osteoblast apopto­
sis is a dominant process in hPTH’s anabolic effects on tra­
becular bone, but it is possible that other biological mecha­
nisms regulate bbPTH’s ability to increase bone mass. For 
example, increasing osteoblast differentiation (rather than 
preventing osteoblast apoptosis) is the primary means by 
which hPTH stimulates periosteal cortical bone formation.
Consistent with this concept, femoral bone strength was 
greatest in mice treated with bbPTH 1-84 (FIG. 29). Bone 
volume fraction in the proximal tibia was also greatest in mice 
treated with bbPTH 1-84 (Table 1), even though bbPTH 1-84 
was less anti-apoptotic than the other peptide analogs tested 
in MC3T3 cells. While the 1-34 fragment of hPTH is suffi­
cient to replicate the anabolic effects of the full hPTH peptide, 
the fact that bbPTH 1-84 demonstrated a superior perfor­
mance in vivo compared to both bbPTH 1 -34 and both hPTH 
peptides suggests that the amino acid changes in bbPTH’s 
C-terminal portion may be involved in receptor binding and 
receptor activation behavior.
Example 15
In Vivo Effects of Human PTH 1 -84 and Bear 
PTH 1-84 in Ovariectomized Rats
Thirty female, 2.5-month old Sprague-Dawley rats were 
ovariectomized (OVX) at the commercial breeding facility 
The OVX animals were randomly assigned into 3 groups of 
10 animals per group for further experiments.
Six weeks after the OVX procedure, the rats were injected 
subcutaneously for an eight-week period (daily for five days 
per week) with vehicle (saline) or 2.5 nmol/kg bear or human 
PTH1-84. Animals were euthanized 24 hours after the last 
injection. Samples were obtained from the euthanized ani­
mals for further analysis.
Femur bending strength and proximal tibia trabecular 
architecture were investigated as described in Example 12.
In this experiment, the ultimate load of the femur was 
significantly (p=0.013) increased by bbPTHl-84 treatment 
compared to vehicle treatment, but not by human PTH1-84 
(p=0.463) (FIG. 20). These findings indicate that bbPTHl-84 
is more efficacious at reversong OVX-induced bone loss in 
rats than human PTH 1 -84 is. Normalized ultimate load of the 
femur, however, was not significantly (p=0.131) affected by 
PTH treatment (FIG. 21). This measure is a more physiologi­
cal measure of bone strength than non-normalized load; it is 
likely bbPTHl-84 would become significanity greater than 
human PTH 1-84 will higher sample sizes to provide greater 
statistical power.
The bone volume fraction was increased in PTH treated 
groups (FIG. 22). The trabecular number was not affected by 
PTH treatment (FIG. 23), although the trabecular thickness 
was increased in PTH treated groups (FIG. 24). The trabecu­
lar separation did not differ between treated and untreated 
groups (FIG. 25). The apparent mineral density increased in 
PTH-treated groups (FIG. 26), but the material mineral den­
sity was not different between the treated and untreated 
groups (FIG. 27). In summary, these data suggest that human 
and black bear PTH 1-84 equivalently increase trabecular 
bone volume (FIG. 26), but bbPTHl-84 shows greater 
increases in cortical bone strength than hPTHl -84 (FIGS. 24 
and 25). These findings suggest bbPTHl -84 has the potential 
to be an efficacious osteoporosis drug for humans.
Example 16
Hibernation Bear Serum Reduces Caspase Activity 
In Vitro
Serum was collected from 6 black bears every 10 days from 
early November till the beginning of May, for a total of 6 
active pre-hibernation (November-December), 9 hibernation 
(January-March), and 4 active post-hibernation (April-May) 
samples from each bear. To determine whether bear serum has
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seasonal effects on osteoblast response to apoptotic stimulus, 
MC3T3-E1 pre-osteoblasts were seeded in Alpha-Modified 
Minimum Essential Media (-MEM) with 10% fetal bovine 
serum at 10,000 cells per well in a white-walled tissue culture 
plate and allowed to attach overnight. Media was then aspi- 5 
rated and replaced with 2% seasonal bear serum in -MEM for 
a 24 hour treatment. Media was again aspirated and replaced 
with serum free -MEM for 6 hours to induce apoptosis. 
Media was aspirated a final time and replaced with 50 uL of
33
PBS and 50 uL of luminescent DEVD substrate (Caspase-glo 
3/7, Promega, Madison, Wis.). Luminescence was quantified 
on a Syneigy HT Multi-Detection Microplate Reader (Bio- 
Tek, Winooski Vt.). As shown in FIG. 28, caspase-3/7 activity 
of cells cultured in hibernation sera was lower than those 
cultured in active sera (p<0.0001). These findings indicate 
that seasonal changes in circulating factors (e.g., hormones) 
provide an anti-apoptotic effect to osteoblasts during hiber­
nation.
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TABLE 6
Sequences
SEQ
ID
NO Description Sequence
1 Polynuc1eo t i de TCTGTGAGCG AGATACAGTT TATGCATAAC CTGGGCAAAC
encoding black ATCTGAGCTC CATGGAGAGG GTGGAATGGC TGCGGAAGAA
bear PTH1-84 GCTGCAGGAC GTGCACAACT TTGTTGCCCT TGGAGCTCCA
(bbPTHl-84) ACAGCGCACA GAGATGGTGG TTCCCAGAGG CCCCAGAAAA
AGGAAGACAA TGTGCTGGTT GAGAACCATC AAAAAAGTCT
CGGAGAAGCA GACAAAGCTG ATGTGGATGT ATTAACTAAA
GCTAAATCCC AGTGAGAATT C
2 black bear SVSEIQFMHN LGKHLSSMER VEWLRKKLQD VHNFVALGAP
PTH1-84 TAHRDGGSQR PQKKEDNVLV ENHQKSLGEA DKADVDVLTK
(bbPTHl-84) AKSQ
3 Polynuc1eo t i de ATGATGTCTG CGAAAGACAT GGTTAAAGTA ATGATTGTCA
encoding full TGTTTGCAAT TTGTTTTCTT GCAAAATCGG ATGGGAAACC
length black TGTTAAGAAG AGATCTGTGA GCGAGATACA GTTTATGCAT
bear PTH AACCTGGGCA AACATCTGAG CTCCATGGAG AGGGTGGAAT
(bbPTH) GGCTGCGGAA GAAGCTGCAG GACGTGCACA ACTTTGTTGC
CCTTGGAGCT CCAACAGCGC ACAGAGATGG TGGTTCCCAG
AGGCCCCAGA AAAAGGAAGA CAATGTGCTG GTTGAGAACC
ATCAAAAAAG TCTCGGAGAA GCAGACAAAG CTGATGTGGA
TGTATTAACT AAAGCTAAAT CCCAGTGAGA ATTC
4 full length MMSAKDMVKV MIVMFAICFL AKSDGKPVKK RSVSEIQFMH
black bear NLGKHLSSME RVEWLRKKLQ DVHNFVALGA PTAHRDGGSQ
PTH (bbPTH) RPQKKEDNVL VENHQKSLGE ADKADVDVLT KAKSQ
5 monkey PTH1- SVSEIQLMHN LGKHLNSMER VEWLRKKLQD VHNFIALGAP
84 LAPRDAGSQR
AKSQ
PRKKEDNILV ESHEKSLGEA DKADVDVLTK
6 human PTH1- SVSEIQLMHN LGKHLNSMER VEWLRKKLQD VHNFVALGAP
84 (hPTHl-84) LAPRDAGSQR
AKSQ
PRKKEDNVLV ESHEKSLGEA DKADVNVLTK
7 horse PTH1- SVSEIQLMHN LGKHLNSVER VEWLRKKLQD VHNFIALGAP
84 IFHRDGGSQR
TKSQ
PRKKEDNVLI ESHQXSLGEA DKADVDVLSK
8 dog PTH1-84 SVSEIQFMHN LGKHLSSMER VEWLRKKLQD VHNFVALGAP
IAHRDGSSQR
AKSQ
PLKKEDNVLV ESYQKSLGEA DKADVDVLTK
9 cat PTH1-84 SVSEIQFMHN LGKHLSSVER VEWLRRKLQD VHNFVALGAP
IAHRDGGSQR
AKSQ
PRKKEDNVPA ENHQKSLGEA DKADVDVLIK
10 bovine PTH1- AVSEIQFMHN LGKHLSSMER VEWLRKKLQD VHNFVALGAS
84 IAYRDGSSQR
AKPQ
PRKKEDNVLV ESHQKSLGEA DKADVDVLIK
11 pig PTH1-84 SVSEIQLMHN LGKHLSSLER VEWLRKKLQD VHNFVALGAS
IVHRDGGSQR
AKPQ
PRKKEDNVLV ESHQKSLGEA DKAAVDVLIK
12 rat PTH1-84 AVSEIQLMHN LGKHLASVER MQWLRKKLQD VHNFVSLGVQ
MAAREGSYQR
AKSQ
PTKKEENVLV DGNSKSLGEG DKADVDVLVK
13 mouse PTH1- AVSEIQLMHN LGKHLASMER MQWLRRKLQD MHNFVSLGVQ
84 MAARDGSHQK
SKSQ
PTKKEENVLV DGNPKSLGEG DKADVDVLVK
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TABLE 6-continued
Secfuences
SEQ
ID
NO Description Sequence
14 hPTHl-34 SVSEIQLMHN LGKHLNSMER VEWLRKKLQD VHNF
15 bbPTHl-34 SVSEIQFMHN LGKHLSSMER VEWLRKKLQD VHNF
16 bbPTHl-36 SVSEIQFMHN LGKHLSSMER VEWLRKKLQD VHNFVA
SEQUENCE LISTING
<160> NUMBER OF SEQ ID NOS: 16
<210> SEQ ID NO 1 
<211> LENGTH: 261 
<212> TYPE: DNA
<213> ORGANISM: Ursus americanus
<400> SEQUENCE: 1
tctgtgagcg agatacagtt tatgcataac ctgggcaaac atctgagctc catggagagg 60
gtggaatggc tgcggaagaa gctgcaggac gtgcacaact ttgttgccct tggagctcca 120
acagcgcaca gagatggtgg ttcccagagg ccccagaaaa aggaagacaa tgtgctggtt 180
gagaaccatc aaaaaagtct cggagaagca gacaaagctg atgtggatgt attaactaaa 240
gctaaatccc agtgagaatt c 261
<210> SEQ ID NO 2 
<211> LENGTH: 84 
<212> TYPE: PRT
<213> ORGANISM: Ursus americanus
<400> SEQUENCE: 2
Ser Val Ser Glu H e Gin Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15
Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val His
20 25 30
Asn Phe Val Ala Leu Gly Ala Pro Thr Ala His Arg Asp Gly Gly Ser
35 40 45
Gin Arg Pro Gin Lys Lys Glu Asp Asn Val Leu Val Glu Asn His Gin
50 55 60
Lys Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asp Val Leu Thr Lys
65 70 75 80
Ala Lys Ser Gin
<210> SEQ ID NO 3 
<211> LENGTH: 354 
<212> TYPE: DNA
<213> ORGANISM: Ursus americanus
<400> SEQUENCE: 3
atgatgtctg cgaaagacat ggttaaagta atgattgtca tgtttgcaat ttgttttctt 60
gcaaaatcgg atgggaaacc tgttaagaag agatctgtga gcgagataca gtttatgcat 120
aacctgggca aacatctgag ctccatggag agggtggaat ggctgcggaa gaagctgcag 180
gacgtgcaca actttgttgc ccttggagct ccaacagcgc acagagatgg tggttcccag 240
aggccccaga aaaaggaaga caatgtgctg gttgagaacc atcaaaaaag tctcggagaa 300
37
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-continued
gcagacaaag ctgatgtgga tgtattaact aaagctaaat cccagtgaga attc
<210> SEQ ID NO 4 
<211> LENGTH: 115 
<212> TYPE: PRT
<213> ORGANISM: Ursus americanus
<400> SEQUENCE: 4
Met Met Ser Ala Lys Asp Met Val Lys Val Met lie Val Met Phe Ala
1 5 10 15
H e Cys Phe Leu Ala Lys Ser Asp Gly Lys Pro Val Lys Lys Arg Ser
20 25 30
Val Ser Glu lie Gin Phe Met His Asn Leu Gly Lys His Leu Ser Ser
35 40 45
Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val His Asn
50 55 60
Phe Val Ala Leu Gly Ala Pro Thr Ala His Arg Asp Gly Gly Ser Gin
65 70 75 80
Arg Pro Gin Lys Lys Glu Asp Asn Val Leu Val Glu Asn His Gin Lys
85 90 95
Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asp Val Leu Thr Lys Ala
100 105 110
Lys Ser Gin
115
<210> SEQ ID NO 5 
<211> LENGTH: 84 
<212> TYPE: PRT
<213> ORGANISM: Macaca fascicularis
<400> SEQUENCE: 5
Ser Val Ser Glu lie Gin Leu Met His Asn Leu Gly Lys His Leu Asn
1 5 10 15
Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val His
20 25 30
Asn Phe lie Ala Leu Gly Ala Pro Leu Ala Pro Arg Asp Ala Gly Ser
35 40 45
Gin Arg Pro Arg Lys Lys Glu Asp Asn lie Leu Val Glu Ser His Glu
50 55 60
Lys Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asp Val Leu Thr Lys
65 70 75 80
Ala Lys Ser Gin
<210> SEQ ID NO 6
<211> LENGTH: 84
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 6
Ser Val Ser Glu lie Gin Leu Met His Asn Leu Gly Lys His Leu Asn 
1 5  10 15
Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val His 
20 25 30
Asn Phe Val Ala Leu Gly Ala Pro Leu Ala Pro Arg Asp Ala Gly Ser 
35 40 45
Gin Arg Pro Arg Lys Lys Glu Asp Asn Val Leu Val Glu Ser His Glu 
50 55 60
354
39
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40
-continued
Lys Ser 
65
Ala Lys
Leu Gly Glu Ala Asp Lys Ala Asp Val Asn Val Leu Thr Lys 
70 75 80
Ser Gin
<210> SEQ ID NO 7
<211> LENGTH: 84
<212> TYPE: PRT
<213> ORGANISM: Equus caballus
<220> FEATURE:
<221> NAME/KEY: misc_feature 
<222 > LOCATION: (65).. (65)
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid
<400> SEQUENCE: 7
Ser Val Ser Glu lie Gin Leu Met His Asn Leu Gly Lys His Leu Asn
1 5 10 15
Ser Val Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val His
20 25 30
Asn Phe H e Ala Leu Gly Ala Pro lie Phe His Arg Asp Gly Gly Ser
35 40 45
Gin Arg Pro Arg Lys Lys Glu Asp Asn Val Leu lie Glu Ser His Gin
50 55 60
Xaa Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asp Val Leu Ser Lys
65 70 75 80
Thr Lys Ser Gin
<210> SEQ ID NO 8
<211> LENGTH: 84
<212> TYPE: PRT
<213> ORGANISM: Canis lupus
<400> SEQUENCE: 8
Ser Val Ser Glu lie Gin Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15
Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val His
20 25 30
Asn Phe Val Ala Leu Gly Ala Pro lie Ala His Arg Asp Gly Ser Ser
35 40 45
Gin Arg Pro Leu Lys Lys Glu Asp Asn Val Leu Val Glu Ser Tyr Gin
50 55 60
Lys Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asp Val Leu Thr Lys
65 70 75 80
Ala Lys Ser Gin
<210> SEQ ID NO 9
<211> LENGTH: 84
<212> TYPE: PRT
<213 > ORGANISM: Felis catus
<400> SEQUENCE: 9
Ser Val Ser Glu lie 
1 5
Ser Val Glu Arg Val 
2 0
Asn Phe Val Ala Leu 
35
Gin Arg Pro Arg Lys 
50
Gin Phe Met His Asn Leu Gly Lys His Leu Ser 
10 15
Glu Trp Leu Arg Arg Lys Leu Gin Asp Val His 
25 30
Gly Ala Pro lie Ala His Arg Asp Gly Gly Ser 
40 45
Lys Glu Asp Asn Val Pro Ala Glu Asn His Gin 
55 60
41
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42
-continued
Lys Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asp Val Leu lie Lys
65 70 75 80
Ala Lys Ser Gin
<210> SEQ ID NO 10
<211> LENGTH: 84
<212> TYPE: PRT
<213> ORGANISM: Bos taurus
<400> SEQUENCE: 10
Ala Val Ser Glu H e Gin Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15
Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val His
20 25 30
Asn Phe Val Ala Leu Gly Ala Ser lie Ala Tyr Arg Asp Gly Ser Ser
35 40 45
Gin Arg Pro Arg Lys Lys Glu Asp Asn Val Leu Val Glu Ser His Gin
50 55 60
Lys Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asp Val Leu lie Lys
65 70 75 80
Ala Lys Pro Gin
<210> SEQ ID NO 11
<211> LENGTH: 84
<212> TYPE: PRT
<213> ORGANISM: Sus scrofa
<400> SEQUENCE: 11
Ser Val Ser Glu lie Gin Leu Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15
Ser Leu Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val His
20 25 30
Asn Phe Val Ala Leu Gly Ala Ser lie Val His Arg Asp Gly Gly Ser
35 40 45
Gin Arg Pro Arg Lys Lys Glu Asp Asn Val Leu Val Glu Ser His Gin
50 55 60
Lys Ser Leu Gly Glu Ala Asp Lys Ala Ala Val Asp Val Leu lie Lys
65 70 75 80
Ala Lys Pro Gin
<210> SEQ ID NO 12
<211> LENGTH: 84
<212> TYPE: PRT
<213> ORGANISM: Rattus norvegicus
<400> SEQUENCE: 12
Ala Val Ser Glu lie Gin Leu Met His Asn Leu Gly Lys His Leu Ala
1 5 10 15
Ser Val Glu Arg Met Gin Trp Leu Arg Lys Lys Leu Gin Asp Val His
20 25 30
Asn Phe Val Ser Leu Gly Val Gin Met Ala Ala Arg Glu Gly Ser Tyr
35 40 45
Gin Arg Pro Thr Lys Lys Glu Glu Asn Val Leu Val Asp Gly Asn Ser
50 55 60
Lys Ser Leu Gly Glu Gly Asp Lys Ala Asp Val Asp Val Leu Val Lys
65 70 75 80
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-continued
Ala Lys Ser Gin
<210> SEQ ID NO 13
<211> LENGTH: 84
<212> TYPE: PRT
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 13
Ala Val Ser Glu H e Gin Leu Met His Asn Leu Gly Lys His Leu Ala
1 5 10 15
Ser Met Glu Arg Met Gin Trp Leu Arg Arg Lys Leu Gin Asp Met His
20 25 30
Asn Phe Val Ser Leu Gly Val Gin Met Ala Ala Arg Asp Gly Ser His
35 40 45
Gin Lys Pro Thr Lys Lys Glu Glu Asn Val Leu Val Asp Gly Asn Pro
50 55 60
Lys Ser Leu Gly Glu Gly Asp Lys Ala Asp Val Asp Val Leu Val Lys
65 70 75 80
Ser Lys Ser Gin
<210> SEQ ID NO 14
<211> LENGTH: 34
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 14
Ser Val Ser Glu lie Gin Leu Met His Asn Leu Gly Lys His Leu Asn 
1 5  10 15
Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val His 
20 25 30
Asn Phe
<210> SEQ ID NO 15 
<211> LENGTH: 34 
<212> TYPE: PRT
<213> ORGANISM: Ursus americanus 
<400> SEQUENCE: 15
Ser Val Ser Glu lie Gin Phe Met His Asn Leu Gly Lys His Leu Ser 
1 5  10 15
Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val His 
20 25 30
Asn Phe
<210> SEQ ID NO 16 
<211> LENGTH: 36 
<212> TYPE: PRT
<213> ORGANISM: Ursus americanus 
<400> SEQUENCE: 16
Ser Val Ser Glu lie Gin Phe Met His Asn Leu Gly Lys His Leu Ser 
1 5  10 15
Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val His 
20 25 30
Asn Phe Val Ala 
35
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What is claimed is:
1. A method of increasing cAMP levels in a bone-forming 
cell comprising administering 0.10 pg/kg per day to 40 pg/kg 
per day of a polypeptide comprising SEQ ID NO: 2 to a 
human subject in need thereof.
2. A method of reducing apoptosis in a bone-forming cell 
comprising administering 0.10 pg/kg per day to 40 pg/kg per 
day of a polypeptide comprising SEQ ID NO: 2 to a human 
subject in need thereof.
3. A method of decreasing the ratio of expression levels of 
Bax protein to Bcl-2 protein in a bone-forming cell compris­
ing administering 0.10 pg/kg per day to 40 pg/kg per day of a 
polypeptide comprising SEQ ID NO: 2 to a human subject in 
need thereof.
4. A method of increasing the expression level of one or 
more of a bone matrix protein, a transcriptional activator, or a 
transcriptional regulator in a bone-forming cell comprising 
administering 0.10 pg/kg per day to 40 pg/kg per day of a 
polypeptide comprising SEQ ID NO: 2 to a human subject in 
need thereof.
5. A method of enhancing bone mineral density, increasing 
bone mass, decreasing bone loss, or reducing the incidence of
bone fractures, or any combination thereof, in a human sub­
ject in need thereof, comprising contacting a bone-forming 
cell in the subject with 0.10 pg/kg per day to 40 pg/kg per day 
of a polypeptide comprising SEQ ID NO: 2.
6. The method of claim 5, wherein the subject is a post­
menopausal female human afflicted with osteoporosis.
7. The method of claim 5 further comprising administering 
vitamin D and calcium to the subject.
8. A method of increasing bone volume, increasing bone 
mineral apparent density, increasing number of trabecular 
struts, increasing thickness of trabecular struts, increasing 
trabecular bone mineralization, increasing cortical bone vol­
ume, decreasing cortical porosity, or decreasing serum cal­
cium, or any combination thereof, in a human subject in need 
thereof, comprising contacting a bone-forming cell in the 
subject with 0.10 pg/kg per day to 40 pg/kg per day of a 
polypeptide comprising SEQ ID NO: 2.
9. The method of claim 8, wherein the subject is a post­
menopausal female human afflicted with osteoporosis.
10. The method of claim 8, further comprising administer­
ing vitamin D and calcium to the subject.
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